TW202411218A - Crystalline forms and preparation methods of hydroxamate compounds and salts thereof - Google Patents

Abstract

The present invention relates to non-solubilized crystals, hydrate crystals, solvated crystals, eutectic crystals, and salt-type crystals of a compound represented by formula (I). .

Description

Crystal form and preparation method of hydroxyoxime ester compound and its salt

The present invention belongs to the field of pharmaceutical chemistry, and specifically relates to the crystal form and preparation method of a hydroxyoxime ester compound and its salt.

6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide is a tyrosine kinase 2 (Tyk2) inhibitor, and its chemical structure is shown in structural formula (I). (I)

The patent application text with PCT patent application number PCT/CN2021/134929 records the pharmacological activity data of the compound represented by formula (I). The compound has excellent Tyk2 selective inhibitory activity and can be used to treat diseases related to abnormal Tyk2 activity. It is expected to obtain better therapeutic effects and fewer side effects in clinical practice.

Currently, there is no information disclosed about the compound represented by formula (I), nor has its crystal form, salt form, and eutectic crystal structure been found, nor has a method for preparing its solvated crystals, solvent-free crystals, salt form, and eutectic crystals been found.

It is known to those skilled in the art that different crystal forms of drugs have a significant impact on the stability, solubility, bioavailability and efficacy of the drugs. Therefore, the study of obtaining the relevant crystals of the compound of formula (I) has an important impact on the subsequent development of the drug and is of great significance. Providing a variety of different crystal forms, salt forms or their co-crystal structures can meet more different clinical needs. Therefore, based on the excellent clinical application prospects of the compound represented by formula (I), it is necessary to further study the microstructures of the crystals, salt forms and co-crystals of the compound represented by formula (I), in order to obtain more microstructures of the compound represented by formula (I) that are beneficial to clinical drug development.

Problem to be solved by the invention : The purpose of the present invention is to provide a crystalline form, a salt form and a co-crystal form of the compound represented by formula (I). Solution to the problem:

In order to solve the above problems, the present invention provides the following technical solutions.

In the first aspect of the present invention, there is provided a non-solubilized crystal of a compound represented by formula (I), (I).

In some specific embodiments, the unsolvated crystals of the compound represented by formula (I) are selected from unsolvated crystals AH and unsolvated crystals E thereof.

In some specific embodiments, the non-solubilized crystals AH of the compound represented by formula (I) have an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 7.65 ^° , 11.26 ^° , 11.43 ^° , 15.07 ^° , 15.32 ^° , 19.07 ^° , 20.12 ^° and 20.78 ^° .

In some specific embodiments, the non-solubilized crystals AH of the compound represented by formula (I) have an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 7.65 ^° , 11.26 ^° , 11.43 ^° , 15.07 ^° , 15.32 ^° , 16.60 ^° , 19.07 ^° , 20.12 ^° , 20.78 ^° and 23.02 ^° .

In some specific embodiments, the non-solubilized crystals AH of the compound represented by formula (I) have an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 7.65 ^° , 9.47 ^° , 11.26 ^° , 11.43 ^° , 15.07 ^° , 15.32 ^° , 16.31 ^° , 16.60 ^° , 19.07 ^° , 20.12 ^° , 20.78 ^° , 23.02 ^° and 25.77 ^° .

In some specific embodiments, the non-solubilized crystals AH of the compound of formula (I) have an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 7.65 ^° , 8.36 ^° , 9.47 ^° , 9.80 ^° , 11.26 ^° , 11.43 ^° , 11.55 ^° , 11.80 ^° , 12.95 ^° , 13.64 ^° , 14.34 ^° , 14.74 ^° , 15.07 ^° , 15.32 ^° , 15.91 ^° , 16.31 ^° , 16.60 ^° , 16.87 ^° , 18.72 ^° , 19.07 ^° , 19.73 ^° , 20.12 ^° , 20.78 ^° , 21.30 ^° , 21.45 ^° , 21.95 ^o , 22.31 ^o , 23.02 ^o , 23.30 ^o , 23.67 ^o , 23.84 ^o , 24.65 ^o , 25.77 ^o , 26.57 ^o , 26.90 ^o , 28.29 ^o , 28.85 ^o , 29.54 ^o .

In some specific embodiments, the X-ray powder diffraction pattern of the non-solubilized crystal AH of the compound represented by formula (I) is shown in FIG7 .

In some specific embodiments, the differential scanning calorimetry curve of the non-solubilized crystal AH of the compound represented by formula (I) shows an endothermic peak near 188 ^° C and an exothermic peak near 216.7 ^° C.

In some specific embodiments, the differential scanning calorimetry curve of the non-solubilized crystal AH of the compound represented by formula (I) is shown in FIG9 .

In some specific embodiments, the thermogravimetric analysis curve of the non-solubilized crystal AH of the compound represented by formula (I) shows that the crystal loses 2.1% of its weight when heated to 150 ^° C, and may decompose after further heating to 190 ^° C.

In some specific embodiments, the thermogravimetric analysis curve of the non-solubilized crystal AH of the compound represented by formula (I) is shown in Figure 10.

In one embodiment, the non-solubilized crystal E of the compound represented by formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 7.19 ^° , 9.59 ^° , 14.46 ^° , 18.15 ^° , 20.41 ^° , 23.44 ^° , 23.67 ^° , 24.01 ^° , 24.34 ^° and 24.60 ^° .

In one embodiment, the non-solubilized crystal E of the compound represented by formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 7.19 ^° , 9.59 ^° , 13.64 ^° , 14.46 ^° , 18.15 ^° , 19.19 ^° , 20.41 ^° , 23.44 ^° , 23.67 ^° , 24.01 ^° , 24.34 ^° and 24.60 ^° .

In one embodiment, the non-solubilized crystal E of the compound represented by formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 7.19 ^° , 8.93 ^° , 9.59 ^° , 12.72 ^° , 13.64 ^° , 14.46 ^° , 18.15 ^° , 19.19 ^° , 19.96 ^° , 20.41 ^° , 23.44 ^° , 23.67 ^° , 24.01 ^° , 24.34 ^° , 24.60 ^° and 28.60 ^° .

In some specific embodiments, the non-solubilized crystal E of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 7.19 ^° , 8.93 ^° , 9.59 ^° , 10.14 ^° , 10.52 ^° , 11.74 ^° , 12.31 ^° , 12.72 ^° , 13.64 ^° , 14.46 ^° , 15.33 ^° , 15.85 ^° , 16.62 ^° , 17.02 ^° , 18.03 ^° , 18.15°, 18.72 ^° , 19.19 ^{° ,} 19.36 ^° , 19.96 ^° , 20.41 ^° , 20.90 ^° , 23.44 ^° , 23.67 ^° , 24.01 ^° , 24.34 ^o , 24.60 ^o , 25.69 ^o , 26.66 ^o , 28.60 ^o , 29.19 ^o , 32.08 ^o .

In one embodiment, the X-ray powder diffraction pattern of the non-solubilized crystal E of the compound represented by formula (I) is shown in Figure 11.

In one embodiment, the differential scanning calorimetry curve of the non-solubilized crystal E of the compound represented by formula (I) shows an endothermic peak at about 194.2 ^° C and an exothermic peak at about 217.1 ^° C.

In one embodiment, the differential scanning calorimetry curve of the non-solubilized crystal E of the compound represented by formula (I) is shown in FIG13 .

In one embodiment, the thermogravimetric analysis curve of the insolubilized crystal E of the compound represented by formula (I) shows that the crystal loses 0.0% of its weight when heated to 150 ^° C, and may decompose after further heating to 190 ^° C.

In one embodiment, the thermogravimetric analysis curve of the non-solubilized crystal E of the compound represented by formula (I) is shown in FIG14 .

In one embodiment, the non-solubilized crystal E of the compound represented by formula (I) has a triclinic crystal form, and the unit cell parameter values are: a = 9.63590(19) Å; b = 10.6920(3) Å; c = 12.4689(2) Å; α = 76.404(2) ^o ; β = 86.6962(16) ^o ; γ = 70.126(2) ^o ; space group: P-1; molecules per unit cell (Z): 2; unit cell volume: 1173.91 Å ³ ; calculated density: 1.376 g/cm ³ .

In a second aspect of the present invention, a hydrate crystal of a compound represented by formula (I) is provided. (I).

In some specific embodiments, the hydrate crystal of the compound represented by formula (I) is selected from hydrate crystal AA, hydrate crystal T, hydrate crystal V and hydrate crystal L thereof.

In some specific embodiments, the hydrate crystal AA of the compound represented by formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 7.85 ^° , 10.35 ^° , 12.74 ^° , 14.95 ^° , 17.94 ^° , 18.05 ^° , 19.01 ^° , 20.90 ^° and 27.26 ^° .

In some specific embodiments, the hydrate crystal AA of the compound represented by formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 7.85 ^° , 8.92 ^° , 10.35 ^° , 11.18 ^° , 12.74 ^° , 14.95 ^° , 17.94 ^° , 18.05 ^° , 19.01 ^° , 20.90 ^° , 24.39 ^° and 27.26 ^° .

In some specific embodiments, the hydrate crystal AA of the compound represented by formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 7.85 ^° , 8.62 ^° , 8.92 ^° , 10.35 ^° , 11.18 ^° , 12.74 ^° , 14.95 ^° , 16.71 ^° , 17.94 ^° , 18.05 ^° , 19.01 ^° , 19.99 ^° , 20.90 ^° , 21.57 ^° , 24.39 ^° and 27.26 ^° .

In some specific embodiments, the hydrate crystal AA of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 7.85 ^° , 8.62 ^° , 8.92 ^° , 10.35 ^° , 10.80 ^° , 11.18 ^° , 12.74 ^° , 14.95 ^° , 15.64 ^° , 16.14 ^° , 16.71 ^° , 17.18 ^° , 17.63 ^° , 17.94 ^° , 18.05 ^° , 18.73 ^° , 19.01 ^° , 19.53 ^° , 19.99 ^° , 20.63 ^° , 20.90 ^° , 21.57 ^° , 22.25 ^° , 22.54 ^° , 22.81 ^° , 23.18 ^o , 23.79 ^o , 24.39 ^o , 24.90 ^o , 25.16 ^o , 25.86 ^o , 26.08 ^o , 27.26 ^o , 27.50 ^o , 27.93 ^o , 28.16 ^o , 28.32 ^o , 29.73 ^o , 31.97 ^o , 34.26 ^o .

In some specific embodiments, the X-ray powder diffraction pattern of the hydrate crystal AA of the compound represented by formula (I) is shown in FIG3 .

In some specific embodiments, the hydrate crystal T of the compound represented by formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 4.31 ^° , 6.09 ^° , 6.82 ^° , 11.05 ^° , 18.49 ^° , 19.74 ^° , 24.32 ^° and 26.78 ^° .

In some specific embodiments, the hydrate crystal T of the compound represented by formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 4.31 ^° , 6.09 ^° , 6.82 ^° , 11.05 ^° , 13.03 ^° , 16.41 ^° , 18.49 ^° , 19.74 ^° , 22.26 ^° , 24.32 ^° and 26.78 ^° .

In some specific embodiments, the hydrate crystal T of the compound represented by formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 4.31 ^° , 6.09 ^° , 6.82 ^° , 8.65°, 11.05 ^° , 13.03 ^° , 13.56 ^° , 16.41 ^° , 17.94 ^° , 18.49 ^° , 19.74 ^° , 22.26 ^° , 24.32 ^° and 26.78 ^° .

In one embodiment, the hydrate crystal T of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 4.31 ^° , 6.09 ^° , 6.53 ^° , 6.82 ^° , 8.65 ^° , 11.05 ^° , 12.27 ^° , 13.03 ^° , 13.56 ^° , 13.74 ^° , 15.46 ^° , 15.64 ^° , 16.41 ^° , 17.52 ^° , 17.94 ^° , 18.49 ^° , 19.60 ^° , 19.74 ^° , 21.86 ^° , 22.26 ^° , 23.01 ^° , 24.32 ^° , 24.49 ^° , 24.73 ^° , 26.78 ^° , 27.09 ^° , 27.83 ^o , 31.20 ^o , 33.11 ^o .

In some specific embodiments, the X-ray powder diffraction pattern of the hydrate crystal T of the compound represented by formula (I) is shown in Figure 20.

In some specific embodiments, the hydrate crystal V of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 6.34 ^° , 7.48 ^° , 7.95 ^° , 10.27 ^° , 12.97 ^° , 17.90 ^° , 20.71 ^° and 23.98 ^° .

In some specific embodiments, the hydrate crystal V of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 6.34 ^° , 7.48 ^° , 7.95 ^° , 9.72 ^° , 10.27 ^° , 12.97 ^° , 17.90 ^° , 20.71 ^° and 23.98 ^° .

In some specific embodiments, the hydrate crystal V of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 6.34 ^° , 7.48 ^° , 7.95 ^° , 9.72 ^° , 10.27 ^° , 12.97 ^° , 14.34 ^° , 17.90 ^° , 18.19 ^° , 20.71 ^° and 23.98 ^° .

In some specific embodiments, the hydrate crystal V of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 6.34 ^° , 7.48 ^° , 7.95 ^° , 9.72 ^° , 10.27 ^° , 12.97 ^° , 14.34 ^° , 15.72 ^° , 16.94 ^° , 17.90 ^° , 18.19 ^° , 19.39 ^° , 20.28 ^° , 20.71 ^° , 21.09 ^° , 22.50 ^° , 23.04 ^° , 23.98 ^° .

In some specific embodiments, the hydrate crystal V of the compound of formula (I) has an X-ray powder diffraction pattern as shown in Figure 22.

In some specific embodiments, the hydrate crystal L of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 6.69 ^° , 8.02 ^° , 9.93 ^° , 14.23 ^° , 16.13 ^° , 16.29 ^° , 18.13 ^° , 19.18 ^° and 24.32 ^° .

In some specific embodiments, the hydrate crystal L of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 6.69 ^° , 8.02 ^° , 9.93 ^° , 12.87 ^° , 14.23 ^° , 16.13 ^° , 16.29 ^° , 18.13 ^° , 19.18 ^° , 21.07 ^° , 23.38 ^° and 24.32 ^° .

In some specific embodiments, the hydrate crystal L of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 6.69 ^° , 7.07 ^° , 8.02 ^° , 9.93 ^° , 12.87 ^° , 14.23 ^° , 16.13 ^° , 16.29 ^° , 17.47 ^° , 18.13 ^° , 19.18 ^° , 21.07 ^° , 23.38 ^° , 24.32 ^° and 28.21 ^° .

In some specific embodiments, the hydrate crystal L of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 6.32 ^° , 6.69 ^° , 7.07 ^° , 8.02 ^° , 9.93 ^° , 12.87 ^° , 14.23 ^° , 15.16 ^° , 15.57 ^° , 16.13 ^° , 16.29 ^° , 16.50 ^° , 16.87 ^° , 17.47 ^° , 18.13 ^° , 19.18 ^° , 19.43 ^° , 20.02 ^° , 21.07 ^° , 21.55 ^° , 21.93 ^° , 22.26 ^° , 23.38 ^° , 23.96 ^° , 24.32 ^° , 24.99° ^o , 25.43 ^o , 25.75 ^o , 26.98 ^o , 27.86 ^o , 28.21 ^o , 29.51 ^o , 29.94 ^o , 31.27 ^o , 33.20 ^o .

In some specific embodiments, the hydrate crystal L of the compound of formula (I) has an X-ray powder diffraction pattern as shown in Figure 26.

In the third aspect of the present invention, there is provided a solvated crystal of a compound represented by formula (I), wherein the solvent is selected from methanol, formic acid, ethanol, (I); wherein the ratio of the compound represented by formula (I) to the solvent is 1:0.3~1.

In some specific embodiments, the solvated crystals of the compound represented by formula (I) are methanol solvated crystals, and the ratio of the compound represented by formula (I) to methanol is 1:0.4~1.

In some specific embodiments, the methanol-solventized crystals of the compound represented by formula (I) are methanol-solventized crystals A.

In some specific embodiments, in the methanol solvent crystal A of the compound represented by formula (I), the ratio of the compound represented by formula (I) to methanol is 1:1.

In some specific embodiments, the methanol solvent crystal A of the compound represented by formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 4.56 ^° , 9.16 ^° , 9.34 ^° , 12.91 ^° , 13.78 ^° , 14.66 ^° , 15.25 ^° , 18.52 ^° and 23.12 ^° .

In some specific embodiments, the methanol solvent crystal A of the compound represented by formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 4.56 ^° , 9.16 ^° , 9.34 ^° , 12.91 ^° , 13.78 ^° , 14.66 ^° , 15.25 ^° , 16.52 ^° , 18.52 ^° , 20.58 ^° , 23.12 ^° , 24.02 ^° and 27.83 ^° .

In some specific embodiments, the methanol-solventized crystal A of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 4.56 ^° , 9.16 ^° , 9.34 ^° , 11.36 ^° , 12.91 ^° , 13.78 ^° , 14.66 ^° , 15.25 ^° , 16.52 ^° , 17.82 ^° , 18.52 ^° , 19.48 ^° , 19.62 ^° , 20.58 ^° , 22.47 ^° , 22.93°, 23.12 ^{° ,} 24.02 ^° , 24.90 ^° , 27.09 ^° , 27.83 ^° , 32.61 ^° , 37.44 ^° .

In some specific embodiments, the methanol solvent crystal A of the compound represented by formula (I) has an X-ray powder diffraction pattern as shown in FIG1 .

In some specific embodiments, the methanol-solventized crystals of the compound represented by formula (I) are methanol-solventized crystals AE.

In some specific embodiments, in the methanol solvent crystals AE of the compound represented by formula (I), the ratio of the compound represented by formula (I) to methanol is 1:0.4.

In one embodiment, the methanol solvent crystal AE of the compound represented by formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 9.08 ^° , 9.63 ^° , 13.11 ^° , 13.70 ^° , 14.80 ^° , 15.29 ^° , 17.88 ^° , 18.78 ^° , 22.94 ^° and 23.46 ^° .

In one embodiment, the methanol solvent crystal AE of the compound represented by formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 9.08 ^° , 9.63 ^° , 13.11 ^° , 13.70 ^° , 14.80 ^° , 15.29 ^° , 16.68 ^° , 17.88 ^° , 18.78 ^° , 20.16 ^° , 22.94 ^° , 23.46 ^° and 25.32 ^° .

In some specific embodiments, the methanol-solventized crystals AE of the compound of formula (I) have an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 4.51 ^° , 9.08 ^° , 9.63 ^° , 11.60 ^° , 13.11 ^° , 13.70 ^° , 14.80 ^° , 15.29 ^° , 15.99 ^° , 16.68 ^° , 17.88 ^° , 18.78 ^° , 20.16 ^° , 22.94 ^° , 23.46 ^° , 25.32 ^° .

In one embodiment, the methanol solvent crystal AE of the compound represented by formula (I) has an X-ray powder diffraction pattern as shown in FIG5 .

In some specific embodiments, the solvated crystals of the compound represented by formula (I) are formic acid solvated crystals, wherein the ratio of the compound represented by formula (I) to formic acid is 1:1.

In some specific embodiments, the formic acid-solventized crystals of the compound represented by formula (I) are selected from formic acid-solventized crystals F, formic acid-solventized crystals O, and formic acid-solventized crystals AF.

In some specific embodiments, the formic acid solvated crystal F of the compound represented by formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 4.96 ^° , 5.30 ^° , 7.25 ^° , 8.44 ^° , 12.14 ^° , 15.04 ^° , 15.83 ^° , 19.47 ^° and 20.11 ^° .

In some specific embodiments, the formic acid solvated crystal F of the compound represented by formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 4.96 ^° , 5.30 ^° , 7.25 ^° , 8.44 ^° , 9.93 ^° , 12.14 ^° , 12.91 ^° , 14.62 ^° , 15.04 ^° , 15.83 ^° , 19.47 ^° and 20.11 ^° .

In some specific embodiments, the formic acid solvent crystal F of the compound represented by formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): about 4.96 ^° , 5.30 ^° , 7.25 ^° , 8.44 ^° , 9.93 ^° , 10.71 ^° , 12.14 ^° , 12.91 ^° , 14.62 ^° , 15.04 ^° , 15.83 ^° , 17.08 ^° , 18.52 ^° , 19.47 ^° , 20.11 ^° , 22.07 ^° , 23.14 ^° , 24.48 ^° , 25.64 ^° .

In some specific embodiments, the formic acid-solventized crystal F of the compound represented by formula (I) has an X-ray powder diffraction pattern as shown in FIG16 .

In some specific embodiments, the formic acid solvated crystalline O has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 5.30 ^° , 10.68 ^° , 11.72 ^° , 15.25 ^° , 16.09 ^° , 17.99 ^° , 20.50 ^° , 22.30 ^° , 25.78 ^° and 26.57 ^° .

In some specific embodiments, the formic acid solvated crystal O of the compound represented by formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 5.30 ^° , 10.54 ^° , 10.68 ^° , 11.72 ^° , 13.73 ^° , 15.25 ^° , 16.09 ^° , 16.96 ^° , 17.99 ^° , 20.50 ^° , 21.00 ^° , 22.30 ^° , 25.78 ^° , 26.57 ^° and 28.89 ^° .

In some specific embodiments, the formic acid solvent crystal O of the compound represented by formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 5.30 ^° , 10.54 ^° , 10.68 ^° , 10.93 ^° , 11.72 ^° , 11.93 ^° , 12.39 ^° , 13.31 ^° , 13.73 ^° , 14.04 ^° , 15.25 ^° , 16.09 ^° , 16.96 ^° , 17.99 ^° , 18.26 ^° , 19.37 ^° , 19.57 ^° , 20.08 ^° , 20.35 ^° , 20.50 ^° , 21.00 ^° , 21.51 ^° , 22.04 ^° , 22.30 ^° , 23.02 ^o , 24.84 ^o , 24.99 ^o , 25.26 ^o , 25.78 ^o , 26.57 ^o , 26.99 ^o , 28.89 ^o , 30.68 ^o , 33.16 ^o .

In some specific embodiments, the formic acid-solventized crystal O of the compound represented by formula (I) has an X-ray powder diffraction pattern as shown in FIG18 .

In some specific embodiments, the formic acid solvated crystals AF of the compound represented by formula (I) have an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 6.19 ^° , 7.48 ^° , 8.32 ^° , 12.49 ^° , 13.46 ^° and 14.76 ^° .

In some specific embodiments, the formic acid solvated crystals AF of the compound represented by formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 6.19 ^° , 7.48 ^° , 8.32 ^° , 12.49 ^° , 12.97 ^° , 13.46 ^° , 14.76 ^° , 17.56 ^° , 23.59 ^° and 25.35 ^° .

In some specific embodiments, the formic acid solvent crystal AF of the compound represented by formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 5.93 ^° , 6.19 ^° , 7.48 ^° , 8.32 ^° , 11.30 ^° , 11.65 ^° , 12.49 ^° , 12.97 ^° , 13.46 ^° , 14.76 ^° , 17.56 ^° , 17.81 ^° , 18.48 ^° , 19.37 ^° , 20.48 ^° , 21.57 ^° , 22.75 ^° , 23.59 ^° , 24.93 ^° , 25.35 ^° .

In some specific embodiments, the formic acid-solventized crystals AF of the compound represented by formula (I) have an X-ray powder diffraction pattern as shown in FIG. 24 .

In some specific embodiments, the ethanol-solventized crystals of the compound represented by formula (I) are ethanol-solventized crystals R, and the ratio of the compound represented by formula (I) to ethanol is 1:0.3.

In some specific embodiments, the ethanol solvate crystal R of the compound represented by formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 8.37 ^° , 12.51 ^° , 16.14 ^° , 17.56 ^° , 17.69 ^° , 18.36 ^° , 18.68 ^° , 19.45 ^° , 21.71 ^° , 23.01 ^° and 24.14 ^° .

In some specific embodiments, the ethanol solvate crystal R of the compound represented by formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 8.37 ^° , 12.51 ^° , 15.04 ^° , 16.14 ^° , 16.59 ^° , 17.56 ^° , 17.69 ^° , 18.36 ^° , 18.68 ^° , 19.45 ^° , 21.71 ^° , 23.01 ^° , 24.14 ^° , 24.98 ^° and 26.58 ^° .

In some specific embodiments, the ethanol solvent crystal R of the compound represented by formula (I) has a X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 8.37 ^° , 12.51 ^° , 13.20 ^° , 13.48 ^° , 14.37 ^° , 15.04 ^° , 15.71 ^° , 16.14 ^° , 16.59 ^° , 16.96 ^° , 17.56 ^° , 17.69 ^° , 18.36 ^° , 18.68 ^° , 19.45 ^° , 19.99°, 20.44 ^{° ,} 21.08 ^° , 21.71 ^° , 22.29 ^° , 23.01 ^° , 23.52 ^° , 23.71 ^° , 24.14 ^° , 24.98 ^o , 25.48 ^o , 26.23 ^o , 26.58 ^o , 27.59 ^o , 28.74 ^o , 29.25 ^o , 30.32 ^o .

In some specific embodiments, the ethanol solvent crystal R of the compound represented by formula (I) has an X-ray powder diffraction pattern as shown in Figure 28.

In a fourth aspect of the present invention, a co-crystal of a compound represented by formula (I) is provided. (I).

In some specific embodiments, the co-crystal of the compound represented by formula (I) is selected from: oxalic acid co-crystal of the compound represented by formula (I), fumaric acid co-crystal of the compound represented by formula (I), citric acid co-crystal of the compound represented by formula (I), apple acid co-crystal of the compound represented by formula (I), and glycolic acid co-crystal of the compound represented by formula (I).

In some specific embodiments, the oxalic acid eutectic crystal of the compound of formula (I) is selected from: oxalic acid eutectic crystal Type A of the compound of formula (I), oxalic acid eutectic crystal Type B of the compound of formula (I), wherein the ratio of the compound of formula (I) to oxalic acid is 1:1.

In some specific embodiments, the oxalic acid cocrystal Type A of the compound of formula (I) has an X-ray powder diffraction pattern with characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 6.07 ^° , 11.01 ^° , 12.23 ^° , 12.80 ^° , 14.28 ^° , 16.93 ^° and 21.76 ^° .

In some specific embodiments, the oxalic acid cocrystal Type A of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 6.07 ^° , 7.07 ^° , 9.41 ^° , 11.01 ^° , 11.46 ^° , 12.23 ^° , 12.80 ^° , 14.28 ^° , 14.63 ^° , 16.93 ^° , 18.49 ^° , 18.95 ^° and 21.76 ^° .

In some specific embodiments, the oxalic acid cocrystal Type A of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 3.58 ^° , 6.07 ^° , 7.07 ^° , 9.41 ^° , 11.01 ^° , 11.46 ^° , 12.23 ^° , 12.80 ^° , 14.28 ^° , 14.63 ^° , 15.55 ^° , 16.93 ^° , 17.97 ^° , 18.49 ^° , 18.95 ^° , 21.76 ^° , 24.91 ^° , 25.72 ^° .

In some specific embodiments, the oxalic acid cocrystal Type A of the compound of formula (I) has an X-ray powder diffraction pattern as shown in Figure 30.

In some specific embodiments, the oxalic acid cocrystal Type B of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 6.01 ^° , 8.19 ^° , 11.55 ^° , 12.34 ^° , 13.79 ^° , 17.36 ^° , 18.14 ^° , 20.56 ^° , 23.27 ^° , 23.94 ^° and 25.24 ^° .

In some specific embodiments, the oxalic acid cocrystal Type B of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 3.60 ^° , 6.01 ^° , 8.19 ^° , 11.55 ^° , 12.34 ^° , 13.79 ^° , 14.52 ^° , 17.36 ^° , 18.14 ^° , 18.98 ^° , 20.56 ^° , 22.30 ^° , 23.27 ^° , 23.94 ^° and 25.24 ^° .

In some specific embodiments, the oxalic acid cocrystal Type B of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 3.60 ^° , 6.01 ^° , 8.19 ^° , 9.41 ^° , 11.55 ^° , 12.05 ^° , 12.34 ^° , 12.77 ^° , 13.79 ^° , 14.25 ^° , 14.52 ^° , 15.64 ^° , 16.43 ^° , 17.36 ^° , 18.14 ^° , 18.98 ^° , 19.69°, 20.56 ^{° ,} 21.40 ^° , 21.93 ^° , 22.30 ^° , 23.27 ^° , 23.94 ^° , 25.24 ^° , 25.77 ^° , 27.76 ^o .

In some specific embodiments, the oxalic acid cocrystal Type B of the compound of formula (I) has an X-ray powder diffraction pattern as shown in Figure 32.

In some specific embodiments, the fumaric acid eutectic crystal of the compound of formula (I) is selected from: fumaric acid eutectic crystal Type B, fumaric acid eutectic crystal Type C, and the ratio of the compound of formula (I) to fumaric acid is 1:1.

In some specific embodiments, the fumaric acid cocrystal Type B of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 5.18 ^° , 6.43 ^° , 10.93 ^° , 11.46 ^° , 12.39 ^° , 15.96 ^° , 16.22 ^° , 19.28 ^° and 22.09 ^° .

In some specific embodiments, the fumaric acid cocrystal Type B of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 3.81 ^° , 5.18 ^° , 6.43 ^° , 8.15 ^° , 9.34 ^° , 10.93 ^° , 11.46 ^° , 12.39 ^° , 15.96 ^° , 16.22 ^° , 19.28 ^° and 22.09 ^° .

In some specific embodiments, the fumaric acid cocrystal Type B of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 3.81 ^° , 5.18 ^° , 6.43 ^° , 7.62 ^° , 8.15 ^° , 9.07 ^° , 9.34 ^° , 10.93 ^° , 11.46 ^° , 12.39 ^° , 15.96 ^° , 16.22 ^° , 19.28 ^° , 22.09 ^° .

In some specific embodiments, the fumaric acid cocrystal Type B of the compound of formula (I) has an X-ray powder diffraction pattern as shown in Figure 40.

In one embodiment, the fumaric acid eutectic crystal Type C has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 7.14 ^° , 7.49 ^° , 10.87 ^° , 12.17 ^° , 17.38 ^° , 19.81 ^° , 20.63 ^° , 21.58 ^° , 23.27 ^° , 24.38 ^° and 25.39 ^° .

In one embodiment, the fumaric acid eutectic crystal Type C has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 7.14 ^° , 7.49 ^° , 8.23 ^° , 10.87 ^° , 12.17 ^° , 16.43 ^° , 17.38 ^° , 17.69 ^° , 19.81 ^° , 20.63 ^° , 21.11 ^° , 21.58 ^° , 23.27 ^° , 24.38 ^° , 25.39 ^° , 28.27 ^° , 29.37 ^° and 31.28 ^° .

In one embodiment, the fumaric acid eutectic crystal Type C has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 7.14 ^° , 7.49 ^° , 8.23 ^° , 10.87 ^° , 12.17 ^° , ^13.24 °, 13.96 ^° , 16.43 ^° , 17.38 ^° , 17.69 ^° , 18.74 ^° , 19.81 ^° , 19.97 ^° , 20.63°, 21.11 ^° , 21.58 ^° , 23.27 ^° , 23.54 ^° , 24.38 ^° , 25.39 ^° , 26.48 ^° , 28.27 ^° , 29.37 ^° , 30.89 ^° , 31.28 ^° , 32.60 ^{° o} .

In one embodiment, the fumaric acid eutectic crystal Type C has an X-ray powder diffraction pattern as shown in Figure 42.

In some specific embodiments, the citric acid co-crystal of the compound of formula (I) is citric acid co-crystal Type A of the compound of formula (I), and the ratio of the compound of formula (I) to citric acid is 1:1.

In some specific embodiments, the citric acid cocrystal Type A of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 5.56 ^° , 6.52 ^° , 9.85 ^° , 14.27 ^° , 14.62 ^° , 16.60 ^° , 17.73 ^° , 19.71 ^° , 19.86 ^° , 24.36 ^° and 26.42 ^° .

In some specific embodiments, the citric acid cocrystal Type A of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 5.56 ^° , 6.52 ^° , 9.85 ^° , 13.20 ^° , 13.46 ^° , 14.27 ^° , 14.62 ^° , 15.78 ^° , 16.60 ^° , 17.73 ^° , 19.71 ^° , 19.86 ^° , 24.36 ^° , 25.16 ^° and 26.42 ^° .

In some specific embodiments, the citric acid cocrystal Type A of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 5.56 ^° , 6.52 ^° , 7.10 ^° , 9.85 ^° , 13.20 ^° , 13.46 ^° , 14.27 ^° , 14.62 ^° , 15.41 ^° , 15.78 ^° , 16.29 ^° , 16.60 ^° , 17.73 ^° , 19.31 ^° , 19.71 ^° , 19.86 ^° , 23.15 ^° , 24.36 ^° , 25.16 ^° and 26.42 ^° .

In some specific embodiments, the citric acid cocrystal Type A of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 5.56 ^° , 6.52 ^° , 7.10 ^° , 9.85 ^° , 11.00 ^° , 12.76 ^° , 13.20 ^° , 13.46 ^° , 14.27 ^° , 14.62 ^° , 15.41 ^° , 15.78 ^° , 16.29 ^° , 16.60 ^° , 17.73 ^° , 19.31 ^° , 19.71° ^, 19.86 ^° , 23.15 ^° , 23.51 ^° , 24.36 ^° , 25.16 ^° , 25.56 ^° , 25.70 ^° , 26.42 ^° , 27.08 ^o , 27.53 ^o , 27.74 ^o , 28.08 ^o , 32.03 ^o .

In some specific embodiments, the citric acid cocrystal Type A of the compound of formula (I) has an X-ray powder diffraction pattern as shown in Figure 58.

In some specific embodiments, the apple acid co-crystal of the compound of formula (I) is apple acid co-crystal Type A of the compound of formula (I), and the ratio of the compound of formula (I) to apple acid is 1:1.

In some specific embodiments, the apple acid cocrystal Type A of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 7.14 ^° , 8.77 ^° , 8.99 ^° , 9.90 ^° , 11.59 ^° , 11.84 ^° , 17.27 ^° , 19.91 ^° , 20.22 ^° , 21.09 ^° , 23.74 ^° and 25.22 ^° .

In some specific embodiments, the apple acid cocrystal Type A of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 7.14 ^° , 8.77 ^° , 8.99 ^° , 9.90 ^° , 11.59 ^° , 11.84 ^° , 17.27 ^° , 18.02 ^° , 19.21 ^° , 19.91 ^° , 20.22 ^° , 21.09 ^° , 22.98 ^° , 23.74 ^° , 24.42 ^° and 25.22 ^° .

In some specific embodiments, the apple acid cocrystal Type A of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 7.14 ^° , 8.77 ^° , 8.99 ^° , 9.90 ^° , 11.59 ^° , 11.84 ^° , 13.90 ^° , 14.72 ^° , 15.83 ^° , 17.27 ^° , 18.02 ^° , 19.21 ^° , 19.91 ^° , 20.22 ^° , 21.09 ^° , 22.98 ^° , 23.74 ^° , 24.42 ^° and 25.22 ^° .

In some specific embodiments, the apple acid cocrystal Type A of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 7.14 ^° , 8.77 ^° , 8.99 ^° , 9.90 ^° , 11.59 ^° , 11.84 ^° , 13.90 ^° , 14.72 ^° , 15.83 ^° , 17.27 ^° , 18.02 ^° , 18.49 ^° , 19.21 ^° , 19.91 ^° , 20.22 ^° , 20.49 ^° , 21.09 ^° , 22.32 ^° , 22.98 ^° , 23.74 ^° , 24.42 ^° , 25.22 ^° , 25.58 ^° , 26.30 ^° , 27.04 ^° , 27.86 ^o , 28.46 ^o , 29.20 ^o , 29.84 ^o , 31.18 ^o , 31.42 ^o , 34.27 ^o , 34.82 ^o .

In some specific embodiments, the apple acid co-crystal Type A of the compound of formula (I) has an X-ray powder diffraction pattern as shown in Figure 60.

In some specific embodiments, the glycolic acid co-crystal of the compound of formula (I) is selected from: glycolic acid co-crystal Type A of the compound of formula (I) and glycolic acid co-crystal Type B of the compound of formula (I), wherein the ratio of the compound of formula (I) to glycolic acid is 1:1.

In some specific embodiments, the glycolic acid cocrystal Type A of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 5.61 ^° , 6.83 ^° , 8.27 ^° , 11.25 ^° , 13.73 ^° , 14.63 ^° , 16.94 ^° , 19.79 ^° and 23.23 ^° .

In some specific embodiments, the glycolic acid cocrystal Type A of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 5.61 ^° , 6.83 ^° , 8.27 ^° , 11.25 ^° , 11.50 ^° , 13.73 ^° , 14.63 ^° , 16.63 ^° , 16.94 ^° , 19.79 ^° , 20.37 ^° , 21.33 ^° , 23.23 ^° and 24.68°.

In some specific embodiments, the glycolic acid cocrystal Type A of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 5.61 ^° , 6.83 ^° , 7.77 ^° , 8.27 ^° , 9.32 ^° , 9.64 ^° , 11.25 ^° , 11.50 ^° , 12.02 ^° , 13.73 ^° , 14.63 ^° , 15.33 ^° , 16.63 ^° , 16.94 ^° , 17.80 ^° , 19.79 ^° , 20.37 ^° , 21.33 ^{° ,} 21.58°, 22.10 ^° , 22.64 ^° , 23.23 ^° , 24.21 ^° , 24.68 ^° , 25.33 ^° , 26.16 ^o , 27.99 ^o , 32.77 ^o .

In some specific embodiments, the glycolic acid cocrystal Type A of the compound of formula (I) has an X-ray powder diffraction pattern as shown in Figure 66.

In some specific embodiments, the glycolic acid cocrystal Type B of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 5.44 ^° , 6.70 ^° , 8.29 ^° , 10.96 ^° , 13.50 ^° , 14.25 ^° , 16.48 ^° , 20.83 ^° and 25.06 ^° .

In some specific embodiments, the glycolic acid cocrystal Type B of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 5.44 ^° , 6.70 ^° , 8.29 ^° , 10.96 ^° , 11.36, 13.50 ^° , 14.25 ^° , 16.48 ^° , 19.66 ^° , 19.92 ^° , 20.48 ^° , 20.83 ^° and 25.06 ^° .

In some specific embodiments, the glycolic acid cocrystal Type B of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 5.44 ^° , 6.70 ^° , 8.29 ^° , 10.96 ^° , 11.36 ^° , 12.07 ^° , 13.50 ^° , 14.25 ^° , 16.48 ^° , 19.66 ^° , 19.92°, 20.48 ^° , 20.83 ^° , ^22.87 , 23.43, 25.06 ^° .

In some specific embodiments, the glycolic acid cocrystal Type B of the compound of formula (I) has an X-ray powder diffraction pattern as shown in Figure 68.

In the fourth aspect of the present invention, a salt form of the compound represented by formula (I) is provided. (I).

In some specific embodiments, the salt form of the compound represented by formula (I) is selected from: its toluenesulfonate salt, its methanesulfonate salt, its potassium salt, its maleate salt, its sodium salt and its hydrochloride salt.

In some specific embodiments, the p-toluenesulfonate of the compound represented by formula (I), wherein the ratio of the compound represented by formula (I) to p-toluenesulfonic acid is 1:1.

In some specific embodiments, the methanesulfonate of the compound represented by formula (I), wherein the ratio of the compound represented by formula (I) to methanesulfonic acid is 1:1-1.2.

In some specific embodiments, the potassium salt of the compound represented by formula (I) has the structure .

In some specific embodiments, the maleate salt of the compound represented by formula (I), wherein the ratio of the compound represented by formula (I) to maleic acid is 1:1.

In some specific embodiments, the sodium salt of the compound represented by formula (I) has the structure .

In some specific embodiments, the hydrochloride of the compound represented by formula (I), wherein the ratio of the compound represented by formula (I) to hydrochloric acid is 1:1.

In a fifth aspect of the present invention, a salt crystal of a compound represented by formula (I) is provided. (I).

In some specific embodiments, the salt crystals of the compound represented by formula (I) are selected from: p-toluenesulfonate crystals thereof, wherein the ratio of the compound represented by formula (I) to p-toluenesulfonic acid is 1:1; methanesulfonate crystals thereof, wherein the ratio of the compound represented by formula (I) to methanesulfonic acid is 1:1 to 1.2; potassium salt crystals thereof, which have the structure ; Its maleate salt crystals, wherein the ratio of the compound represented by formula (I) to maleic acid is 1:1; Its sodium salt crystals, which have the structure ; Its hydrochloride crystals, wherein the ratio of the compound represented by formula (I) to hydrochloric acid is 1:1.

In some specific embodiments, the p-toluenesulfonate crystals of the compound of formula (I) are selected from its p-toluenesulfonate crystals Type A, its p-toluenesulfonate crystals Type B, and its p-toluenesulfonate crystals Type C, wherein the ratio of the compound represented by formula (I) to p-toluenesulfonic acid is 1:1.

In some specific embodiments, the p-toluenesulfonate crystals of the compound of formula (I) Type A have an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 7.41 ^° , 9.57 ^° , 9.92 ^° , 16.06 ^° , 16.94 ^° , 19.70 ^° , 20.44 ^° , 22.07 ^° and 26.24 ^° .

In some specific embodiments, the p-toluenesulfonate crystals of the compound of formula (I) Type A have an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 7.41 ^° , 9.14 ^° , 9.57 ^° , 9.92 ^° , 11.25 ^° , 12.95 ^° , 14.45 ^° , 16.06 ^° , 16.94 ^° , 19.70 ^° , 20.44 ^° , 21.30 ^° , 22.07 ^° , 24.82 ^° , 25.52 ^° and 26.24 ^° .

In some specific embodiments, the p-toluenesulfonate crystals of the compound of formula (I) Type A have an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 7.41 ^° , 9.14 ^° , 9.57 ^° , 9.92 ^° , 10.98 ^° , 11.25 ^° , 12.95 ^° , 14.33 ^° , 14.45 ^° , 15.05 ^° , 15.21 ^° , 15.82 ^° , 16.06 ^° , 16.94 ^° , 17.56 ^° , 17.77 ^° , 18.07 ^° , 18.38 ^° , 19.23 ^° , 19.41 ^° , 19.70 ^° , 20.44 ^° , 21.08 ^° , 21.30 ^° , 22.07 ^° , 22.41 ^o , 22.67 ^o , 23.19 ^o , 23.46 ^o , 24.82 ^o , 25.52 ^o , 26.02 ^o , 26.24 ^o , 28.12 ^o , 28.72 ^o , 30.18 ^o , 30.74 ^o , 32.03 ^o .

In some specific embodiments, the p-toluenesulfonate crystals of the compound of formula (I) Type A have an X-ray powder diffraction pattern as shown in Figure 34.

In some specific embodiments, the p-toluenesulfonate crystalline Type B of the compound of formula (I) has an X-ray powder diffraction pattern with characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 6.35 ^° , 6.93 ^° , 7.63 ^° , 14.59 ^° , 16.79 ^° and 20.79 ^° .

In some specific embodiments, the p-toluenesulfonate crystalline Type B of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 6.35 ^° , 6.93 ^° , 7.63 ^° , 11.29 ^° , 14.59 ^° , 16.79 ^° , 17.72 ^° , 20.79 ^° , 22.25 ^° and 26.56 ^° .

In some specific embodiments, the p-toluenesulfonate crystal Type B of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 6.35 ^° , 6.93 ^° , 7.63 ^° , 8.29 ^° , 11.29 ^° , 12.72 ^° , 14.59 ^° , 16.79 ^° , 17.72 ^° , 19.33 ^° , 20.79 ^° , 22.25 ^° , 23.05 ^° , 25.19 ^° , 26.56 ^° , 27.84 ^° .

In some specific embodiments, the p-toluenesulfonate crystals of the compound of formula (I) Type B have an X-ray powder diffraction pattern as shown in Figure 36.

In some specific embodiments, the p-toluenesulfonate crystalline Type C of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 5.19 ^° , 6.87 ^° , 10.06 ^° , 13.79 ^° , 16.62 ^° , 16.93 ^° , 20.44 ^° , 24.53 ^° and 26.12 ^° .

In some specific embodiments, the p-toluenesulfonate crystal Type C of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 5.19 ^° , 6.87 ^° , 10.06 ^° , 13.79 ^° , 14.79 ^° , 16.62 ^° , 16.93 ^° , 17.23 ^° , 20.44 ^° , 21.03 ^° , 24.53 ^° , 24.93 ^° and 26.12 ^° .

In some specific embodiments, the p-toluenesulfonate crystal Type C of the compound of formula (I) has a characteristic diffraction peak at the following 2θ angles (±0.2 ^° ): 5.19 ^° , 6.87 ^° , 10.06 ^° , 12.06°, 12.72 ^° , 12.95 ^° , 13.58 ^° , 13.79 ^° , 14.17 ^° , 14.46 ^° , 14.79 ^° , ^{16.62 °} , 16.93 ^° , 17.23 ^° , 18.76 ^° , 19.36 ^° , 20.44 ^° , 21.03 ^° , 21.55 ^° , 21.83 ^° , 22.10 ^° , 23.31 ^° , 23.51 ^° , 23.73 ^° , 24.13 ^o , 24.53 ^o , 24.93 ^o , 25.60 ^o , 26.12 ^o , 27.26 ^o , 27.76 ^o , 29.50 ^o , 29.84 ^o , 30.52 ^o .

In some specific embodiments, the p-toluenesulfonate crystals of the compound of formula (I) Type C have an X-ray powder diffraction pattern as shown in Figure 38.

In some specific embodiments, the mesylate crystals of the compound of formula (I) are selected from its mesylate crystals Type A, its mesylate crystals Type B, and its mesylate crystals Type C, wherein the ratio of the compound represented by formula (I) to methanesulfonic acid is 1:1~1.2.

In some specific embodiments, the mesylate crystals of the compound of formula (I) are mesylate crystals Type A, and the ratio of the compound of formula (I) to methanesulfonic acid is 1:1.

In some specific embodiments, the Type A crystalline mesylate of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 8.09 ^° , 9.60 ^° , 11.06 ^° , 12.57 ^° , 14.33 ^° , 14.55 ^° , 16.93 ^° , 19.32 ^° , 19.64 ^° , 20.19 ^° , 20.31 ^° , 21.05 ^° and 26.42 ^° .

In some specific embodiments, the mesylate crystal Type A of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 8.09 ^° , 9.60 ^° , 10.75 ^° , 11.06 ^° , 12.57 ^° , 14.33 ^° , 14.55 ^° , 16.52 ^° , 16.93 ^° , 19.32 ^° , 19.64 ^° , 20.19°, 20.31 ^° , 21.05 ^° , 21.59 ^° , 22.98 ^° , 24.72 ^° , 26.42 ^° , 27.00 ^° and ^{28.30° .}

In some specific embodiments, the mesylate crystal Type A of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 8.09 ^° , 8.69 ^° , 9.60 ^° , 10.75 ^° , 11.06 ^° , 12.02 ^° , 12.57 ^° , 13.85 ^° , 14.33 ^° , 14.55 ^° , 15.33 ^° , 15.89°, 16.52 ^° , 16.93 ^° , 17.39 ^° , 17.67 ^° , 17.93 ^° , 19.32 ^{° ,} 19.64 ^° , 19.96 ^° , 20.19 ^° , 20.31 ^° , 20.65 ^° , 21.05 ^° , 21.59 ^° , 21.78 ^o , 22.25 ^o , 22.51 ^o , 22.70 ^o , 22.98 ^o , 24.52 ^o , 24.72 ^o , 25.26 ^o , 25.89 ^o , 26.42 ^o , 27.00 ^o , 27.41 ^o , 28.30 ^o , 28.55 ^o , 29.47 ^o , 31.47 ^o , 33.70 ^o .

In some specific embodiments, the mesylate crystals of the compound of formula (I) Type A have an X-ray powder diffraction pattern as shown in FIG. 44 .

In some specific embodiments, the mesylate crystals of the compound of formula (I) are its mesylate crystals Type B, and the ratio of the compound of formula (I) to p-methanesulfonic acid is 1:1.2.

In some specific embodiments, the mesylate crystal Type B of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 5.74 ^° , 5.89 ^° , 11.53 ^° , 11.93 ^° , 12.47 ^° , 12.90 ^° , 14.06 ^° , 15.01 ^° , 17.14 ^° and 25.52 ^° .

In some specific embodiments, the mesylate crystal Type B of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 5.74 ^° , 5.89 ^° , 7.66 ^° , 11.53 ^° , 11.93 ^° , 12.47 ^° , 12.90 ^° , 14.06 ^° , 15.01 ^° , 17.14 ^° , 22.60 ^° and 25.52 ^° .

In some specific embodiments, the mesylate crystal Type B of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 5.74 ^° , 5.89 ^° , 7.66 ^° , 7.95 ^° , 8.95 ^° , 10.21 ^° , 11.53 ^° , 11.93 ^° , 12.47 ^° , 12.90 ^° , 14.06 ^° , 15.01°, 17.14 ^° , 17.99 ^° , 20.49 ^° , 22.60 ^° , 23.90 ^° , ^{25.52° ,} 26.39 ^° .

In some specific embodiments, the mesylate crystals of the compound of formula (I) Type B have an X-ray powder diffraction pattern as shown in Figure 46.

In some specific embodiments, the mesylate crystals of the compound of formula (I) are mesylate crystals Type C, and the ratio of the compound of formula (I) to p-methanesulfonic acid is 1:1.

In some specific embodiments, the mesylate crystal Type C of the compound of formula (I) has an X-ray powder diffraction pattern with characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 5.32 ^° , 8.45 ^° , 11.84 ^° , 17.01 ^° , 18.49 ^° , 21.30 ^° and 22.98 ^° .

In some specific embodiments, the mesylate crystal Type C of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 5.32 ^° , 8.45 ^° , 10.30 ^° , 11.84 ^° , 16.06 ^° , 17.01 ^° , 18.49 ^° , 21.30 ^° , 22.98 ^° and 24.30 ^° .

In some specific embodiments, the mesylate crystal Type C of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 5.32 ^° , 8.45 ^° , 10.30 ^° , 11.84 ^° , 14.48 ^° , 14.78 ^° , 15.28 ^° , 16.06 ^° , 17.01 ^° , 18.49 ^° , 20.46 ^° , 20.91°, 21.30 ^° , 22.98 ^° , 23.51 ^° , 24.30 ^° , 24.85 ^° , 25.44 ^° , 25.83 ^° , 28.47 ^° , ^{30.85° .}

In some specific embodiments, the mesylate crystals of the compound of formula (I) Type C have an X-ray powder diffraction pattern as shown in Figure 48.

In some specific embodiments, the potassium salt crystal of the compound of formula (I) is Type A potassium salt crystal thereof.

In some specific embodiments, the potassium salt crystal of the compound of formula (I) Type A has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 5.74 ^° , 6.68 ^° , 7.96 ^° , 13.54 ^° , 14.04 ^° , 17.78 ^° , 20.14 ^° and 23.29 ^° .

In some specific embodiments, the potassium salt crystal Type A of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 5.74 ^° , 6.68 ^° , 7.96 ^° , 11.78 ^° , 13.54 ^° , 14.04 ^° , 15.33 ^° , 17.78 ^° , 19.45 ^° , 20.14 ^° , 23.29 ^° , 24.72 ^° , 26.92 ^° and 28.29 ^° .

In some specific embodiments, the potassium salt crystal Type A of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 5.74 ^° , 6.68 ^° , 7.96 ^° , 11.52 ^° , 11.78 ^° , 13.54 ^° , 14.04 ^° , 14.44 ^° , 15.33 ^° , 16.22 ^° , 16.71 ^° , 17.43 ^° , 17.78 ^° , 18.20 ^° , 18.40°, 18.86 ^° , 19.45 ^° , 20.14 ^° , 20.70 ^° , 22.75 ^° , 23.29 ^° , 24.15 ^° , 24.72 ^° , 26.39 ^° , 26.92 ^{° .} , 27.37 ^o , 27.62 ^o , 28.29 ^o , 31.39 ^o , 36.10 ^o .

In some specific embodiments, the potassium salt crystal of the compound of formula (I) Type A has an X-ray powder diffraction pattern as shown in Figure 50.

In some specific embodiments, the maleate crystals of the compound of formula (I) are selected from: maleate crystals Type A and maleate crystals Type B, wherein the ratio of the compound of formula (I) to maleic acid is 1:1.

In some specific embodiments, the maleate crystal Type A of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 4.26 ^° , 4.76 ^° , 7.08 ^° , 7.96 ^° , 8.54 ^° , 9.53 ^° , 10.18 ^° , 10.93 ^° , 14.34 ^° , 15.03 ^° , 15.99 ^° and 20.50 ^° .

In some specific embodiments, the maleate crystal Type A of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 4.26 ^° , 4.76 ^° , 7.08 ^° , 7.96 ^° , 8.54 ^° , 9.53 ^° , 10.18 ^° , 10.93 ^° , 13.89 ^° , 14.34 ^° , 15.03 ^° , 15.99 ^° , 20.50 ^° , 21.49 ^° and 24.03 ^° .

In some specific embodiments, the maleate crystal Type A of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 4.26 ^° , 4.76 ^° , 7.08 ^° , 7.96 ^° , 8.54 ^° , 9.53 ^° , 10.18 ^° , 10.93 ^° , 12.41 ^° , 13.89 ^° , 14.34 ^° , 15.03°, 15.99 ^° , 17.93 ^° , 20.50 ^° , 21.49 ^° , 23.55 ^° and ^{24.03° .}

In some specific embodiments, the maleate crystal Type A of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 4.26 ^° , 4.76 ^° , 7.08 ^° , 7.96 ^° , 8.54 ^° , 9.53 ^° , 10.18 ^° , 10.93 ^° , 12.41 ^° , 13.89 ^° , 14.34 ^° , 15.03°, 15.99 ^° , 17.93 ^° , 20.50 ^° , 21.49 ^° , 21.97 ^° , 23.55 ^° , 24.03 ^° , 25.19 ^° , 25.57 ^° , ^{26.00° .}

In some specific embodiments, the maleate crystals of the compound of formula (I) Type A have an X-ray powder diffraction pattern as shown in Figure 52.

In some specific embodiments, the maleate crystal Type B of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 4.34 ^° , 4.79 ^° , 5.27 ^° , 7.20 ^° , 7.86 ^° , 10.22 ^° , 10.56 ^° , 11.08 ^° , 14.73 ^° , 15.20 ^° , 16.14 ^° and 20.50 ^° .

In some specific embodiments, the maleate crystal Type B of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 4.34 ^° , 4.79 ^° , 5.27 ^° , 7.20 ^° , 7.86 ^° , 10.22 ^° , 10.56 ^° , 11.08 ^° , 11.81 ^° , 14.44 ^° , 14.73 ^° , 15.20 ^° , 16.14 ^° and 20.50 ^° .

In some specific embodiments, the maleate crystal Type B of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 4.34 ^° , 4.79 ^° , 5.27 ^° , 7.20 ^° , 7.86 ^° , 8.63 ^° , 9.60 ^° , 10.22 ^° , 10.56 ^° , 11.08 ^° , 11.81 ^° , 13.94 ^{°, 14.44° ,} 14.73 ^° , 15.20 ^° , 16.14 ^° , 20.50 ^° , 21.25 ^° , 21.83 ^° , 26.32 ^° .

In some specific embodiments, the maleate crystals of the compound of formula (I) Type B have an X-ray powder diffraction pattern as shown in Figure 54.

In some specific embodiments, the sodium salt crystal of the compound of formula (I) is Type B sodium salt crystal thereof.

In some specific embodiments, the sodium salt crystal Type B of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 6.01 ^° , 6.61 ^° , 7.94 ^° , 11.88 ^° , 12.48 ^° , 13.10 ^° , 13.70 ^° , 18.31 ^° , 19.98 ^° , 21.19 ^° , 22.35 ^° , 25.36 ^° and 26.27 ^° .

In some specific embodiments, the sodium salt crystal Type B of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 6.01 ^° , 6.61 ^° , 7.94 ^° , 11.88 ^° , 12.48 ^° , 13.10 ^° , 13.31 ^° , 13.70 ^° , 16.52 ^° , 17.48 ^° , 18.31 ^° , 19.98 ^° , 21.19 ^° , 22.35 ^° , 24.81 ^° , 25.36 ^° and 26.27 ^° .

In some specific embodiments, the sodium salt crystal Type B of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 6.01 ^° , 6.61 ^° , 7.94 ^° , 11.88 ^° , 12.48 ^° , 13.10 ^° , 13.31 ^° , 13.70 ^° , 14.96 ^° , 15.25 ^° , 16.52 ^° , 17.48 ^° , 18.31 ^° , 19.07 ^° , 19.98 ^° , 20.59 ^° , 21.19 ^° , 22.35 ^° , 23.86 ^° , 24.81 ^° , 25.36 ^° , 26.27 ^° , 27.78 ^° , 28.28 ^° , 31.15 ^° , 31.79 ^o .

In some specific embodiments, the sodium salt crystals of the compound of formula (I) Type B have an X-ray powder diffraction pattern as shown in Figure 56.

In some specific embodiments, the hydrochloride crystals of the compound of formula (I) are selected from its hydrochloride crystals Type A and its hydrochloride crystals Type B, wherein the ratio of the compound of formula (I) to hydrochloric acid is 1:1.

In some specific embodiments, the hydrochloride crystals of the compound of formula (I) Type A have an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 5.90 ^° , 7.42 ^° , 7.74 ^° , 10.96 ^° , 14.07 ^° , 14.96 ^° , 18.01 ^° , 25.14 ^° and 26.42 ^° .

In some specific embodiments, the hydrochloride crystal Type A of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 5.90 ^° , 7.42 ^° , 7.74 ^° , 10.96 ^° , 11.56 ^° , 12.15 ^° , 14.07 ^° , 14.96 ^° , 18.01 ^° , 21.93 ^° , 23.42 ^° , 25.14 ^° and 26.42 ^° .

In some specific embodiments, the hydrochloride crystal Type A of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 5.90 ^° , 7.42 ^° , 7.74 ^° , 10.96 ^° , 11.56 ^° , 12.15 ^° , 13.39 ^° , 14.07 ^° , 14.96 ^° , 17.60 ^° , 18.01 ^° , 19.26°, 19.70 ^° , 21.55 ^° , 21.93 ^° , 23.42 ^° , 25.14 ^° , 25.56 ^° , 26.42 ^° , 27.71 ^° , 28.84 ^° , ^{29.26° .}

In some specific embodiments, the hydrochloride crystals of the compound of formula (I) Type A have an X-ray powder diffraction pattern as shown in Figure 62.

In some specific embodiments, the hydrochloride crystal Type B of the compound of formula (I) has an X-ray powder diffraction pattern with characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 6.48 ^° , 7.20 ^° , 7.90 ^° , 14.16 ^° , 14.48 ^° , 15.68 ^° , 17.31 ^° , 21.76 ^° and 26.53 ^° .

In some specific embodiments, the hydrochloride crystal Type B of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 5.42 ^° , 6.48 ^° , 7.20 ^° , 7.90 ^° , 12.85 ^° , 13.01 ^° , 14.16 ^° , 14.48 ^° , 15.68 ^° , 17.31 ^° , 19.36 ^° , 21.76 ^° , 22.91 ^° and 26.53 ^° .

In some specific embodiments, the hydrochloride crystal Type B of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 4.80 ^° , 5.42 ^° , 6.48 ^° , 7.20 ^° , 7.90 ^° , 10.00 ^° , 13.50 ^° , 10.39 ^° , 12.85 ^° , 13.01 ^° , 14.16 ^° , 14.48°, 15.68 ^° , 17.31 ^° , 19.36 ^° , 19.64 ^° , 21.76 ^° , 22.91 ^{° ,} 23.86 ^° , 24.40 ^° , 25.72 ^° , 25.95 ^° , 26.14 ^° , 26.53 ^° , 28.53 ^° , 31.86 ^o .

In some specific embodiments, the hydrochloride crystals of the compound of formula (I) Type B have an X-ray powder diffraction pattern as shown in Figure 64. Description:

Unless otherwise specified, the ratios of solvate crystals, eutectic crystals or salt-type crystals described in the present invention are all molar ratios.

In the present invention, "solvate" and "solvate compound" have the same meaning and can be interchanged.

In the present invention , "crystal" and "crystal form" have the same meaning and can be interchanged.

The present invention provides a variety of new crystal forms, salt forms and co-crystal forms of the compound represented by formula (I) to meet different clinical needs.

The content of the present invention is further explained below in conjunction with examples. It should be understood that the terms used herein are intended to describe specific implementation schemes and are not intended to be limiting. The numerical ranges described in the specification, such as measurement units, reaction conditions, physical states of compounds or percentages, are all for the purpose of providing clear and unambiguous written references. When practicing this patent, skilled technicians in this field can still obtain the expected results by using temperatures, concentrations, quantities, carbon atom numbers, etc. outside this range or different from single values. Any methods, devices and materials similar or equivalent to those described herein for implementing or testing the present invention are within the scope of protection of this application.

Note: Unless otherwise specified, the percentages mentioned in this invention are all weight percentages. Unless otherwise specified, the ratios of solvate crystals, eutectic crystals or salt crystals in this invention are all molar ratios. Test conditions and test methods:

X-ray powder diffraction test conditions: instrument: Panalytical EMPYREAN (PANalytical, Netherlands); radiation source: Cu-Kα (40 kV, 40 mA).

X-ray single crystal diffraction test conditions: instrument: SXtaLAB Synergy R (Rigaku, Japan); radiation source: Cu target light source, λ = 1.54184 Å; test temperature: 150.0 K; data processing: CrysAlisPro software package was used for analysis and processing.

Differential scanning calorimetry test conditions: instrument: TA Discovery 2500 (TA, USA); heating rate: 10 ^o C/min; nitrogen flow rate: 50mL/min.

Thermogravimetric analysis test conditions: instrument: TA Discovery 55 (TA, USA); heating rate: 10 ^° C/min; nitrogen flow rate: nitrogen purge rate at the sample is 60 mL/min, nitrogen purge rate at the balance is 40 mL/min.

Dynamic moisture adsorption and desorption analysis test conditions: Instrument: DVS Intrinsic (SMS, UK); Humidity change gradient: The test adopts gradient mode, the humidity change is 50%-95%-0%-50%, and the humidity change of each gradient in the range of 0% to 90% is 10%. The gradient end point is judged by dm/dt method, and the gradient end point is dm/dt less than 0.002% and maintained for 10 minutes. After the test is completed, the sample is analyzed by XRPD to confirm whether the solid form has changed.

Proton NMR test conditions: instrument: AV-400 (BRUKER, Germany); solvent: DMSO-d6.

Stability test conditions (Examples 40-44): According to Appendix XIX C of Part II of the Chinese Pharmacopoeia 2010 edition, high temperature (60 ^o C), high humidity (90%) and strong light irradiation (4500Lx) tests were carried out.

Centrifugation conditions: instrument: Dalong D3024; speed: 10000 rpm; time: 3 min.

Definition of terms: Description of hygroscopic characteristics and definition of hygroscopic weight gain (Chinese Pharmacopoeia 2015 General Rules 9103 Guiding Principles for Hygroscopic Test of Drugs, Experimental conditions: 25 ^° C±1 ^° C, 80% relative humidity): Deliquescent: Absorbs enough water to form a liquid; Very hygroscopic: Hygroscopic weight gain is not less than 15.0%; Hygroscopic: Hygroscopic weight gain is less than 15.0% but not less than 2.0%; Slightly hygroscopic: Hygroscopic weight gain is less than 2.0% but not less than 0.2%; No or almost no hygroscopicity: Hygroscopic weight gain is less than 0.2%. Example A : Preparation of compound of formula ( I ):

The structure of the compound is determined by nuclear magnetic resonance (NMR) or mass spectrometry (MS). NMR measurements are performed using a Bruker ASCENA-400 nuclear magnetic spectrometer, with deuterated dimethyl sulfoxide (DMSO -d ₆ ), deuterated chloroform (CDCl ₃ ), deuterated methanol (CD ₃ OD) as the solvent, tetramethylsilane (TMS) as the internal standard, and chemical shifts are given in units of 10 ^-6 (ppm).

The reaction was monitored and analyzed by MS using a Thermofisher ESQ (ESI) mass spectrometer.

The HPLC determination was performed using a Thermo Fisher U3000 DAD high pressure liquid chromatograph (GL Sciences ODS-HL HP 3 μm 3.0*100 mm column).

The silica plate used for thin layer chromatography (TLC) is GF254 silica plate from Qingdao Ocean. The silica plate used for thin layer chromatography (TLC) is of 0.15-0.2 mm in size. The product used for TLC separation and purification is a high-efficiency TLC preparative plate of 0.9-1.0 mm in size. Column chromatography uses 200-300 mesh silica from Qingdao Ocean as a carrier. The developing agents used are A: dichloromethane and methanol system; B: petroleum ether and ethyl acetate system. The volume ratio of the solvent is adjusted according to the polarity of the compound. The medium pressure preparative liquid phase purification uses the biotage isera one type preparative liquid phase.

All reaction materials can be purchased from manufacturers such as Saan Chemical Technology (Shanghai) Co., Ltd., Shanghai Shaoyuan Reagent Co., Ltd., Nanjing Yaoshi Technology Co., Ltd., Jiangsu Aikang Biopharmaceutical Research and Development Co., Ltd., and Shanghai Bid Pharmaceutical Technology Co., Ltd. 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide

Step 1: 3-bromo-2-methoxyaniline ( 212-a , 2.8 g, 13.86 mmol), pinacol diborate (5.3 g, 20.79 mmol), Pd(dppf) _Cl2 (1.03 g, 1.39 mmol) and potassium acetate (4.08 g, 41.58 mmol) were added to the dioxane solution in sequence. The mixture was evacuated and replaced with nitrogen three times. Stirring was continued at 110°C for 20 hours. The reaction was completed as monitored by TLC and the reaction solution was completely concentrated. Water (40 mL) was added to the reaction solution, extracted with ethyl acetate (30 mL x 2), washed with saturated brine (30 mL x 2), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was separated and purified by silica gel column chromatography (ethyl acetate: petroleum ether = 1:4) to obtain 2-methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline ( 212-b , 2.3 g, 9.23 mmol, 66% yield). MS Calcd: 249.15; MS Found: 250.01 ([M+H] ⁺ ).

Step 2: 2-methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline ( 212-b , 2.3 g, 9.23 mmol) and Boc anhydride (2.41 g, 11.07 mmol) were placed in 10 mL of ethanol solvent and stirred at room temperature overnight. The reaction was completed by TLC monitoring, the filtrate was concentrated, and the residue was separated and purified by silica gel column chromatography (ethyl acetate: petroleum ether = 1:4) to obtain (2-methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)tert-butyl-1-azaalkanecarboxylate ( 212-c , 2.4 g, 8 mmol, 86% yield). MS Calcd: 348.20; MS Found: 250.16 ([M-100] ⁺ ).

Step 3: (2-methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)tert-butyl-1-azaalkanecarboxylate ( 212-c , 370 mg, 1.06 mmol), 2-bromopyrimidine (200 mg, 1.27 mmol), potassium phosphate (521 mg, 2.46 mmol) and Pd(dppf) _Cl2 (59 mg, 0.082 mmol) were added to a mixed solution of 7 mL of water and dioxane (6:1), evacuated, replaced with nitrogen three times, and stirred at 105°C for 10 hours. The reaction was completed by TLC monitoring, and the reaction solution was completely concentrated. The residue was separated and purified by silica gel column chromatography (ethyl acetate: petroleum ether = 1:1) to obtain (2-methoxy-3-(pyrimidin-2-yl)phenyl)-2-azolinic acid tert-butyl ester ( 212-d , 150 mg, 0.5 mmol, 39% yield). MS Calcd: 300.13; MS Found: 301.12 ([M+H] ⁺ ).

Step 4: Dissolve (2-methoxy-3-(pyrimidin-2-yl)phenyl)-2-azoxycarbonyl tert-butyl ester ( 212-d , 150 mg, 0.5 mmol) in dichloromethane solution, then add trifluoroacetic acid (421 mg, 3.7 mmol), stir at room temperature for 5 h, monitor the completion of the reaction by TLC, completely concentrate the reaction solution, add saturated sodium bicarbonate solution to the residue, extract with dichloromethane, wash with saturated brine, dry with anhydrous sodium sulfate, concentrate under reduced pressure, and separate and purify the residue by silica gel column chromatography to obtain the product 2-methoxy-3-(pyrimidin-2-yl)aniline ( 212-e , 70 mg, 0.35 mmol, 70% yield). MS Calcd: 201.23; MS Found: 202.10 ([M+H] ⁺ ).

Step 5: 2-methoxy-3-(pyrimidin-2-yl)aniline ( 212-e , 70 mg, 0.35 mmol) and 4,6-dichloro-N-ethoxynicotinamide (74 mg, 0.32 mmol) were added to 5 ml of anhydrous N,N-dimethylacetamide, and a tetrahydrofuran solution of LiHMDS (1.28 ml, 1.28 mmol) was added at room temperature. The mixture was stirred at room temperature for 3 hours. The reaction was completed when monitored by TLC. The pH was adjusted to 5 with hydrochloric acid (4N), and the mixture was extracted with ethyl acetate (20 ml x 3). The organic layers were combined, dried, concentrated, and purified by silica gel column chromatography (PE:EA =1:2) to give 6-chloro-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide ( 212-f , 110 mg, 0.27 mmol, 72% yield). MS Calcd: 399.11; MS Found: 400.11 ([M+H] ⁺ ).

Step 6: 6-Chloro-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinoylamide ( 212-f , 110 mg, 0.27 mmol), 4-amino-2,6-dimethylpyrimidine (44 mg, 0.36 mmol), cesium carbonate (195 mg, 0.6 mmol), XantPhos (25 mg, 0.04 mmol) and _Pd2 (dba) ₃ (27 mg, 0.029 mmol) were added to anhydrous dioxane (2 ml) and evacuated, replaced with nitrogen three times, heated to 125°C, stirred for 10 hours, filtered, the filtrate was concentrated, and purified by preparative TLC (MeOH:DCM=1:20) to obtain the title compound: 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinate ( 212 , 20 mg, 0.04 mmol, 15% yield). MS Calcd: 486.21; MS Found: 487.21 ([M+H] ⁺ ). ¹ H NMR (400 MHz, DMSO-d ₆ ) δ 11.70 (s, 1H), 10.22 (s, 1H), 10.10 (s, 1H), 8.95 (d, J = 4.8 Hz, 2H), 8.39 (s, 1H), 8.17 (s, 1H), 7.73 (dd, J = 8.0, 1.6 Hz, 1H), 7.51 (t, J = 4.8 Hz, 1H), 7.46 (dd, J = 8.0, 1.6 Hz, 1H), 7.32 (t, J = 8.0 Hz, 1H), 7.09 (s, 1H), 3.96 (q, J = 7.2 Hz, 2H), 3.70 (s, 3H), 2.39 (s, 3H), 2.28 (s, 3H), 1.23 (t, J = 7.2 Hz, 3H). Example 1 : Formula ( I ) Preparation of methanol-solvent crystals of compound A

Place 19.3 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide in a 4 mL EP tube, add 1.2 mL of methanol, heat at 50 ^° C until completely dissolved, then quickly transfer the solution to 25 ^° C and cool to crystallize. Crystallize for 3 hours, centrifuge and collect the solid, and simmer at 25 ^° C. C and vacuum dried for 24 hours to obtain a sample. The obtained sample was subjected to XRPD test and proton nuclear magnetic resonance analysis, and its X-ray powder diffraction pattern was shown in Figure 1, and its proton nuclear magnetic resonance spectrum was shown in Figure 2. Figure 2 shows that the crystal contains methanol, wherein the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to methanol is 1:1. Example 2 : Preparation of hydrate crystals AA of 6-(((2,6 -dimethylpyrimidin -4- yl ) amino )-N- ethoxy - 4-((2- methoxy - 3-( pyrimidin -2- yl ) phenyl ) amino ) nicotinamide

20.6 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 10 mL EP tube, 10 mL of water was added, the mixture was heated to 50 ^° C and suspended and stirred for 24 hours, and then the suspension was centrifuged and separated, and the obtained solid was vacuum dried at 25 ^° C for 24 hours to obtain a sample. The obtained sample was subjected to XRPD test and proton nuclear magnetic resonance analysis, and its X-ray powder diffraction pattern was shown in Figure 3, and its proton nuclear magnetic resonance spectrum was shown in Figure 4. Figure 4 shows that the crystal does not contain an organic solvent. Example 3 : Preparation of methanol-solvent crystals of 6-(((2,6 -dimethylpyrimidin -4- yl ) amino )-N- ethoxy -4-((2- methoxy -3-( pyrimidin -2- yl ) phenyl ) amino ) nicotinamide AE

20.7 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, 1.0 mL of methanol was added, and the suspension was stirred at 25 ^° C for 7 days. The suspension was separated by centrifugation, and the solid was collected and heated at 25 ^{° C.} C and vacuum dried for 24 hours to obtain a sample. The obtained sample was subjected to XRPD test and proton nuclear magnetic resonance analysis, and its X-ray powder diffraction pattern was shown in Figure 5, and its proton nuclear magnetic resonance spectrum was shown in Figure 6. Figure 6 shows that the crystal contains methanol, wherein the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to methanol is 1:0.4. Example 4 : Preparation of non-solvent crystals AH of 6-(((2,6 -dimethylpyrimidin -4- yl ) amino )-N- ethoxy - 4-((2- methoxy - 3-( pyrimidin -2- yl ) phenyl ) amino ) nicotinamide

Place 591.4 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide in a 40 mL glass bottle, add 3 mL of tetrahydrofuran, stir at 25 ^° C to dissolve it, and after the solvent evaporates, heat the resulting solid at 120 ^° C for about 30 minutes, then place the resulting solid at 80 ^{° C.} C vacuum drying for 18 hours to obtain a sample. The obtained sample was subjected to XRPD test, differential scanning calorimetry analysis, thermogravimetric analysis and proton nuclear magnetic resonance analysis, and its X-ray powder diffraction pattern was shown in Figure 7, its proton nuclear magnetic resonance spectrum was shown in Figure 8, its differential scanning calorimetry curve was shown in Figure 9, and its thermogravimetric analysis curve was shown in Figure 10. Figure 8 shows that the crystal does not contain an organic solvent. Example 5 : Preparation of non- solventized crystals E of 6-(((2,6 -dimethylpyrimidin -4- yl ) amino )-N- ethoxy -4-((2- methoxy -3-( pyrimidin -2- yl ) phenyl ) amino ) nicotinamide

602.2 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 40 mL glass bottle, 21 mL of ethyl acetate was added, and the mixture was suspended and stirred at 50 ^° C for 24 hours. The suspension was then centrifuged and separated, and the obtained solid was vacuum dried at 40 ^° C for 24 hours to obtain a sample. The obtained sample was subjected to XRPD test, differential scanning calorimetry analysis, thermogravimetric analysis and proton nuclear magnetic resonance analysis, and its X-ray powder diffraction pattern was shown in Figure 11, its proton nuclear magnetic resonance spectrum was shown in Figure 12, its differential scanning calorimetry curve was shown in Figure 13, and its thermogravimetric analysis curve was shown in Figure 14. Figure 12 shows that the crystal does not contain an organic solvent. Example 6 ： Preparation of single crystal of non-solvent crystal E of 6-(((2,6 -dimethylpyrimidin -4- yl ) amino )-N - ethoxy -4-((2- methoxy -3-( pyrimidin -2- yl ) phenyl ) amino ) nicotinamide

20.9 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, 2.6 mL of acetonitrile was added, and the mixture was heated at 50 ^° C to dissolve. The solution was then cooled to 25 ^° C. A single crystal was selected from the obtained plate-like crystals, and its X-ray single crystal diffraction pattern was measured at 150 K. As shown in Figure 15, the unit cell parameters were measured as follows: Crystal form: triclinic system a = 9.63590(19) Å; b = 10.6920(3) Å; c = 12.4689(2) Å; α = 76.404(2) ^o ; β = 86.6962(16) ^o ; γ = 70.126(2) ^o ; Space group: P-1; Molecules per unit cell (Z): 2; Unit cell volume: 1173.91 Å ³ ; Calculated density: 1.376 g/cm ³ Example 7 : Preparation of formic acid solution crystals F of 6-(((2,6 -dimethylpyrimidin -4- yl ) amino )-N- ethoxy -4-((2- methoxy - 3-( pyrimidin - 2- yl ) phenyl ) amino ) nicotinamide

20.2 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, 10 mL of butyl formate was added, and the suspension was stirred at 25 ^° C for 7 days. The suspension was separated by centrifugation, and the solid was collected and heated at 25 ^{° C.} C and vacuum dried for 24 hours to obtain a sample. The obtained sample was subjected to XRPD test and proton nuclear magnetic resonance analysis, and its X-ray powder diffraction pattern was shown in Figure 16, and its proton nuclear magnetic resonance spectrum was shown in Figure 17. Figure 17 shows that the crystal contains formic acid, wherein the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to formic acid is 1:1. Example 8 : Preparation of formic acid solvent complex crystal O of 6-(((2,6 -dimethylpyrimidin -4- yl ) amino )-N- ethoxy -4-((2- methoxy - 3-( pyrimidin -2- yl ) phenyl ) amino ) nicotinamide

Place 20.0 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide in a 4 mL EP tube, add 2.0 mL of ethyl formate, heat to 50 ^° C, suspend and stir for 24 hours, then centrifuge the suspension to separate the solid at 25 ^°C. C vacuum drying for 24 hours to obtain a sample. The obtained sample was subjected to XRPD test and proton nuclear magnetic resonance analysis, and its X-ray powder diffraction pattern was shown in Figure 18, and its proton nuclear magnetic resonance spectrum was shown in Figure 19. Figure 19 shows that the crystal contains formic acid, wherein the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to formic acid is 1:1. Example 9 : Preparation of hydrate crystal T of 6-(((2,6 -dimethylpyrimidin -4- yl ) amino )-N- ethoxy -4-((2- methoxy - 3- ( pyrimidin -2- yl ) phenyl ) amino ) nicotinamide

43.6 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, 3.0 mL of water was added, and the mixture was suspended and stirred at 25 ^° C for 7 days. The suspension was then centrifuged and separated, and the obtained solid was vacuum dried at 25 ^° C for 24 hours to obtain a sample. The obtained sample was subjected to XRPD test and proton nuclear magnetic resonance analysis, and its X-ray powder diffraction pattern was shown in Figure 20, and its proton nuclear magnetic resonance spectrum was shown in Figure 21. Figure 21 shows that the crystal does not contain an organic solvent. Example 10 : Preparation of hydrate crystal V of 6-(((2,6 -dimethylpyrimidin -4- yl ) amino )-N- ethoxy -4-((2- methoxy -3-( pyrimidin -2- yl ) phenyl ) amino ) nicotinamide

46.5 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, 0.5 mL of water and 0.5 mL of isopropanol were added, and the mixture was suspended and stirred at 25 ^° C for 7 days. The suspension was then centrifuged and separated, and the obtained solid was vacuum dried at 25 ^° C for 24 hours to obtain a sample. The obtained sample was subjected to XRPD test and proton nuclear magnetic resonance analysis, and its X-ray powder diffraction pattern was shown in Figure 22, and its proton nuclear magnetic resonance spectrum was shown in Figure 23. Figure 23 shows that the crystal does not contain an organic solvent. Example 11 : Preparation of 6-(((2,6 -dimethylpyrimidin -4- yl ) amino )-N- ethoxy -4-((2- methoxy -3-( pyrimidin -2- yl ) phenyl ) amino ) nicotinamide in formic acid solvent crystal AF

Place 20.1 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide in a 10 mL EP tube, add 3.2 mL of methanol and 6.0 mL of ethyl formate at 25 ^° C to dissolve ^it completely. C and left to evaporate in an open container for 7 days until the evaporation was complete, thereby obtaining a sample. The obtained sample was subjected to XRPD test and proton nuclear magnetic resonance analysis, and its X-ray powder diffraction pattern was shown in Figure 24, and its proton nuclear magnetic resonance spectrum was shown in Figure 25. Figure 25 shows that the crystal contains an organic solvent, formic acid, wherein the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to formic acid is 1:1. Example 12 : Preparation of hydrate crystal L of 6-(((2,6 -dimethylpyrimidin -4 - yl ) amino )-N -ethoxy -4-((2- methoxy -3-( pyrimidin -2- yl ) phenyl ) amino ) nicotinamide

21.7 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 10 mL EP tube, 1.8 mL of acetone was added at 25 ^° C to completely dissolve it, and then 6.0 mL of n-heptane was added dropwise to precipitate a solid, which was stirred and crystallized at 25 ^° C for 24 hours. The solid-liquid mixture was then centrifuged and separated, and the obtained solid was vacuum dried at 25 ^° C for 24 hours to obtain a sample. The obtained sample was subjected to XRPD test and proton nuclear magnetic resonance analysis, and its X-ray powder diffraction pattern was shown in Figure 26, and its proton nuclear magnetic resonance spectrum was shown in Figure 27. Figure 27 shows that the crystal does not contain an organic solvent. Example 13 : Preparation of 6-(((2,6 -dimethylpyrimidin -4- yl ) amino )-N- ethoxy -4-((2- methoxy -3-( pyrimidin -2- yl ) phenyl ) amino ) nicotinamide ethanol solvent crystal R

21.1 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 10 mL EP tube, 0.6 mL of ethanol was added, and the suspension was stirred at 25 ^° C for 7 days. The suspension was then centrifuged and the resulting solid was concentrated at 25 ^{° C.} C vacuum drying for 24 hours to obtain a sample. The obtained sample was subjected to XRPD test and proton nuclear magnetic resonance analysis, and its X-ray powder diffraction pattern was shown in Figure 28, and its proton nuclear magnetic resonance spectrum was shown in Figure 29. Figure 29 shows that the crystal contains ethanol, wherein the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide and ethanol is 1:0.3. Example 14 : Preparation of oxalic acid eutectic crystal Type A of 6-(((2,6 -dimethylpyrimidin -4- yl ) amino )-N- ethoxy -4-((2- methoxy - 3- ( pyrimidin -2- yl ) phenyl ) amino ) nicotinamide

29.2 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, 0.5 mL of methanol and 5.6 mg of oxalic acid were added, and the suspension was stirred at 25 ^° C for 2 days. The suspension was separated by centrifugation, and the solid was collected and heated at 25 ^{° C.} C and vacuum dried for 24 hours to obtain a sample. The obtained sample was subjected to XRPD test and proton nuclear magnetic resonance analysis, and its X-ray powder diffraction pattern was shown in Figure 30, and its proton nuclear magnetic resonance spectrum was shown in Figure 31. Figure 31 shows that the crystal contains oxalic acid, and the proton nuclear magnetic resonance spectrum is compared with the proton nuclear magnetic resonance spectrum of the E crystal form. There is no obvious chemical shift offset, and the crystal form is judged to be a cocrystal, wherein the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to oxalic acid is 1:1. Example 15 : Preparation of Oxalic Acid Cocrystal Type B of 6-(((2,6 -dimethylpyrimidin -4- yl ) amino )-N- ethoxy -4-((2- methoxy -3-( pyrimidin -2- yl ) phenyl ) amino ) nicotinamide

29.3 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, 1 mL of ethyl acetate and 5.6 mg of oxalic acid were added, and the suspension was stirred at 25 ^° C for 2 days. The suspension was separated by centrifugation, and the solid was collected and heated at 40 ^{° C.} C and vacuum dried for 24 hours to obtain a sample. The obtained sample was subjected to XRPD test and proton nuclear magnetic resonance analysis, and its X-ray powder diffraction pattern was shown in Figure 32, and its proton nuclear magnetic resonance spectrum was shown in Figure 33. Figure 33 shows that the crystal contains oxalic acid, and the proton nuclear magnetic resonance spectrum is compared with the proton nuclear magnetic resonance spectrum of the E crystal form. There is no obvious chemical shift offset, and the crystal form is judged to be a cocrystal, wherein the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to oxalic acid is 1:1. Example 16 : Preparation of Type A Crystalline 6-(((2,6 -dimethylpyrimidin -4- yl ) amino )-N- ethoxy -4-((2- methoxy -3-( pyrimidin -2- yl ) phenyl ) amino ) nicotinamide p-toluenesulfonate

28.6 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, 0.5 mL of methanol and 11.8 mg of p-toluenesulfonic acid were added, and the suspension was stirred at 25 ^° C for 2 days. The suspension was separated by centrifugation, and the solid was collected and heated at 25 ^{° C.} C and vacuum dried for 24 hours to obtain a sample. The obtained sample was subjected to XRPD test and proton nuclear magnetic resonance analysis, and its X-ray powder diffraction pattern was shown in Figure 34, and its proton nuclear magnetic resonance spectrum was shown in Figure 35. Figure 35 shows that the crystal contains p-toluenesulfonic acid, and the proton nuclear magnetic resonance spectrum has an obvious chemical shift offset compared with the proton nuclear magnetic resonance spectrum of the E crystal form, and it is judged that the crystal form is a salt-forming crystal, wherein the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to p-toluenesulfonic acid is 1:1. Example 17 : Preparation of Type B Crystalline 6-(((2,6 -dimethylpyrimidin -4- yl ) amino )-N- ethoxy -4-((2- methoxy -3-( pyrimidin -2- yl ) phenyl ) amino ) nicotinamide p-toluenesulfonate

27.8 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, 1.0 mL of 4-methyl-2-pentanone and 11.6 mg of p-toluenesulfonic acid were added, and the suspension was stirred at 25 ^° C for 2 days, and the suspension was separated by centrifugation, and the solid was collected and heated at 25 ^{° C.} C and vacuum dried for 24 hours to obtain a sample. The obtained sample was subjected to XRPD test and proton nuclear magnetic resonance analysis, and its X-ray powder diffraction pattern was shown in Figure 36, and its proton nuclear magnetic resonance spectrum was shown in Figure 37. Figure 37 shows that the crystal contains p-toluenesulfonic acid, and the proton nuclear magnetic resonance spectrum has an obvious chemical shift offset compared with the proton nuclear magnetic resonance spectrum of the E crystal form, and it is judged that the crystal form is a salt-forming crystal, wherein the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to p-toluenesulfonic acid is 1:1. Example 18 : Preparation of Type C Crystalline 6-(((2,6 -dimethylpyrimidin -4- yl ) amino )-N- ethoxy -4-((2- methoxy -3-( pyrimidin -2- yl ) phenyl ) amino ) nicotinamide p-toluenesulfonate

29.1 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, 1.0 mL of ethyl acetate and 11.3 mg of p-toluenesulfonic acid were added, and the suspension was stirred at 25 ^° C for 2 days, and the suspension was separated by centrifugation, and the solid was collected and heated at 40 ^{° C.} C and vacuum dried for 24 hours to obtain a sample. The obtained sample was subjected to XRPD test and proton nuclear magnetic resonance analysis, and its X-ray powder diffraction pattern was shown in Figure 38, and its proton nuclear magnetic resonance spectrum was shown in Figure 39. Figure 39 shows that the crystal contains p-toluenesulfonic acid, and the proton nuclear magnetic resonance spectrum has an obvious chemical shift offset compared with the proton nuclear magnetic resonance spectrum of the E crystal form, and it is judged that the crystal form is a salt-forming crystal, wherein the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to p-toluenesulfonic acid is 1:1. Example 19 : Preparation of Fumaric Acid Cocrystal Type B of 6-(((2,6 -dimethylpyrimidin -4- yl ) amino )-N- ethoxy -4-((2- methoxy -3-( pyrimidin -2- yl ) phenyl ) amino ) nicotinamide

29.1 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, 1.0 mL of 4-methyl-2-pentanone and 7.1 mg of fumaric acid were added, and the suspension was stirred at 25 ^° C for 2 days, and then the suspension was centrifuged and the solid was collected and heated at 25 ^{° C.} C and vacuum dried for 24 hours to obtain a sample. The obtained sample was directly subjected to XRPD test and proton nuclear magnetic resonance analysis, and its X-ray powder diffraction pattern was shown in Figure 40, and its proton nuclear magnetic resonance spectrum was shown in Figure 41. Figure 41 shows that the crystal contains fumaric acid, and the proton nuclear magnetic resonance spectrum is compared with the proton nuclear magnetic resonance spectrum of the E crystal form, and there is no obvious chemical shift offset, and the crystal form is judged to be a cocrystal, wherein the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to fumaric acid is 1:1. Example 20 : Preparation of Fumaric Acid Cocrystal Type C of 6-(((2,6 -dimethylpyrimidin -4- yl ) amino )-N- ethoxy -4-((2- methoxy -3-( pyrimidin -2- yl ) phenyl ) amino ) nicotinamide

29.2 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, 1.0 mL of ethyl acetate and 7.2 mg of fumaric acid were added, and the suspension was stirred at 25 ^° C for 2 days. The suspension was separated by centrifugation, and the solid was collected and heated at 40 ^°C . C and vacuum dried for 24 hours to obtain a sample. The obtained sample was subjected to XRPD test and proton nuclear magnetic resonance analysis, and its X-ray powder diffraction pattern was shown in Figure 42, and its proton nuclear magnetic resonance spectrum was shown in Figure 43. Figure 43 shows that the crystal contains fumaric acid, and the proton nuclear magnetic resonance spectrum is compared with the proton nuclear magnetic resonance spectrum of the E crystal form. There is no obvious chemical shift offset, and the crystal form is judged to be a cocrystal, wherein the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to fumaric acid is 1:1. Example 21 : Preparation of Type A Crystalline Methanesulfonate of 6-(((2,6 -dimethylpyrimidin -4- yl ) amino )-N- ethoxy -4-((2- methoxy -3-( pyrimidin -2- yl ) phenyl ) amino ) nicotinamide

28.7 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, 0.5 mL of methanol and 60 μL of a 1 mol/L ethanol solution of methanesulfonic acid were added, and the suspension was stirred at 25 ^° C for 2 days. The suspension was centrifuged and the solid was collected and simmered at 25 ^°C . C and vacuum dried for 24 hours to obtain a sample. The obtained sample was subjected to XRPD test and proton nuclear magnetic resonance analysis, and its X-ray powder diffraction pattern was shown in Figure 44, and its proton nuclear magnetic resonance spectrum was shown in Figure 45. Figure 45 shows that the crystal contains methanesulfonic acid, and the proton nuclear magnetic resonance spectrum has an obvious chemical shift offset compared with the proton nuclear magnetic resonance spectrum of the E crystal form, and it is judged that the crystal form is a salt-forming crystal, wherein the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to methanesulfonic acid is 1:1. Example 22 : Preparation of Type B Methanesulfonate Crystals of 6-(((2,6 -dimethylpyrimidin -4- yl ) amino )-N- ethoxy -4-((2- methoxy -3-( pyrimidin -2- yl ) phenyl ) amino ) nicotinamide

29.5 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, 1.0 mL of 4-methyl-2-pentanone and 60 μL of a 1 mol/L ethanol solution of methanesulfonic acid were added, and the suspension was stirred at 25 ^° C for 2 days. The suspension was separated by centrifugation, and the solid was collected and simmered at 25 ^°C . C and vacuum dried for 24 hours to obtain a sample. The obtained sample was subjected to XRPD test and proton nuclear magnetic resonance analysis, and its X-ray powder diffraction pattern was shown in Figure 46, and its proton nuclear magnetic resonance spectrum was shown in Figure 47. Figure 47 shows that the crystal contains methanesulfonic acid, and the proton nuclear magnetic resonance spectrum has an obvious chemical shift offset compared with the proton nuclear magnetic resonance spectrum of the E crystal form, and it is judged that the crystal form is a salt-forming crystal, wherein the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to methanesulfonic acid is 1:1.2. Example 23 : Preparation of Type C Methanesulfonate Crystals of 6-(((2,6 -dimethylpyrimidin -4- yl ) amino )-N- ethoxy -4-((2- methoxy -3-( pyrimidin -2- yl ) phenyl ) amino ) nicotinamide

Place 29.5 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide in a 4 mL EP tube, add 1.0 mL of ethyl acetate and 60 uL of 1 mol/L methanesulfonic acid ethanol solution, and stir at 25 ^° C for 2 days. Centrifuge the suspension, collect the solid, and simmer at 40 ^°C . C and vacuum dried for 24 hours to obtain a sample. The obtained sample was subjected to XRPD test and proton nuclear magnetic resonance analysis, and its X-ray powder diffraction pattern was shown in Figure 48, and its proton nuclear magnetic resonance spectrum was shown in Figure 49. Figure 49 shows that the crystal contains methanesulfonic acid, and the proton nuclear magnetic resonance spectrum has an obvious chemical shift offset compared with the proton nuclear magnetic resonance spectrum of the E crystal form, and it is judged that the crystal form is a salt-forming crystal, wherein the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to methanesulfonic acid is 1:1. Example 24 : Preparation of Type A Crystalline Potassium Salt of 6-(((2,6 -dimethylpyrimidin -4- yl ) amino )-N- ethoxy -4-((2- methoxy -3-( pyrimidin -2- yl ) phenyl ) amino ) nicotinamide

28.5 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, 1.0 mL of 4-methyl-2-pentanone and 3.7 mg of potassium hydroxide were added, and the suspension was stirred at 25 ^° C for 2 days. The suspension was separated by centrifugation, and the solid was collected and heated at 25 ^{° C.} C and vacuum dried for 24 hours to obtain a sample. The obtained sample was subjected to XRPD test and proton nuclear magnetic resonance analysis, and its X-ray powder diffraction pattern was shown in Figure 50, and its proton nuclear magnetic resonance spectrum was shown in Figure 51. Figure 51 shows that its proton nuclear magnetic resonance spectrum has obvious chemical shift offset compared with the proton nuclear magnetic resonance spectrum of the E crystal form, and it is judged that the crystal form is a salt-forming crystal. Example 25 : Preparation of Type A maleate crystals of 6-(((2,6 -dimethylpyrimidin -4- yl ) amino )-N- ethoxy -4-((2- methoxy -3-( pyrimidin -2- yl ) phenyl ) amino ) nicotinamide

28.8 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, 7.0 mg of maleic acid and 1.0 mL of 4-methyl-2-pentanone were added, and the suspension was stirred at 25 ^° C for 2 days. The suspension was separated by centrifugation, and the solid was collected and heated at 25 ^{° C.} C and vacuum dried for 24 hours to obtain a sample. The obtained sample was subjected to XRPD test and proton nuclear magnetic resonance analysis, and its X-ray powder diffraction pattern was shown in Figure 52, and its proton nuclear magnetic resonance spectrum was shown in Figure 53. Figure 53 shows that its proton nuclear magnetic resonance spectrum has obvious chemical shift offset compared with the proton nuclear magnetic resonance spectrum of the E crystal form, and it is judged that the crystal form is a salt-forming crystal, wherein the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to maleic acid is 1:1. Example 26 : Preparation of Type B Crystalline Maleate of 6-(((2,6 -dimethylpyrimidin -4- yl ) amino )-N- ethoxy -4-((2- methoxy -3-( pyrimidin -2- yl ) phenyl ) amino ) nicotinamide

29.3 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, 7.0 mg of maleic acid and 2.0 mL of ethyl acetate were added, and the suspension was stirred at 25 ^° C for 2 days. The suspension was separated by centrifugation, and the solid was collected and heated at 25 ^{° C.} C and vacuum dried for 24 hours to obtain a sample. The obtained sample was subjected to XRPD test and proton nuclear magnetic resonance analysis, and its X-ray powder diffraction pattern was shown in Figure 54, and its proton nuclear magnetic resonance spectrum was shown in Figure 55. Figure 55 shows that its proton nuclear magnetic resonance spectrum has obvious chemical shift offset compared with the proton nuclear magnetic resonance spectrum of the E crystal form, and it is judged that the crystal form is a salt-forming crystal, wherein the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to maleic acid is 1:1. Example 27 : Preparation of 6-(((2,6 -dimethylpyrimidin -4- yl ) amino )-N- ethoxy -4-((2- methoxy -3-( pyrimidin -2- yl ) phenyl ) amino ) nicotinamide sodium salt crystal Type B

29.2 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, 2.6 mg of sodium hydroxide and 1.0 mL of ethyl acetate were added, and the suspension was stirred at 25 ^° C for 2 days. The suspension was separated by centrifugation, and the solid was collected and heated at 25 ^{° C.} C and vacuum dried for 24 hours to obtain a sample. The obtained sample was subjected to XRPD test and proton nuclear magnetic resonance analysis, and its X-ray powder diffraction pattern was shown in Figure 56, and its proton nuclear magnetic resonance spectrum was shown in Figure 57. Figure 57 shows that its proton nuclear magnetic resonance spectrum has obvious chemical shift offset compared with the proton nuclear magnetic resonance spectrum of the E crystal form, and it is judged that the crystal form is a salt-forming crystal. Example 28 : Preparation of Citrate Cocrystal Type A of 6-(((2,6 -dimethylpyrimidin -4- yl ) amino )-N- ethoxy -4-((2- methoxy -3-( pyrimidin -2- yl ) phenyl ) amino ) nicotinamide

28.8 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, 11.6 mg of citric acid and 1.0 mL of 4-methyl-2-pentanone were added, and the suspension was stirred at 25 ^° C for 2 days. The suspension was separated by centrifugation, and the solid was collected and heated at 25 ^{° C.} C and vacuum dried for 24 hours to obtain a sample. The obtained sample was subjected to XRPD test and proton nuclear magnetic resonance analysis, and its X-ray powder diffraction pattern was shown in Figure 58, and its proton nuclear magnetic resonance spectrum was shown in Figure 59. Figure 59 shows that its proton nuclear magnetic resonance spectrum has no obvious chemical shift offset compared with the E crystal proton nuclear magnetic resonance spectrum, and it is determined that no salification has been formed, wherein 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide: citric acid = 1: 1. Example 29 : Preparation of Type A cocrystal of 6-(((2,6 -dimethylpyrimidin -4- yl ) amino )-N- ethoxy -4-((2- methoxy -3-( pyrimidin -2- yl ) phenyl ) amino ) nicotinamide with apple acid

29.0 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, 1.0 mL of 4-methyl-2-pentanone and 8.1 mg of apple acid were added, and the suspension was stirred at 25 ^° C for 2 days. The suspension was centrifuged and the solid was collected and heated at 25 ^{° C.} C and vacuum dried for 24 hours to obtain a sample. The obtained sample was subjected to XRPD test and proton nuclear magnetic resonance analysis, and its X-ray powder diffraction pattern was shown in Figure 60, and its proton nuclear magnetic resonance spectrum was shown in Figure 61. Figure 61 shows that the crystal contains apple acid, and the proton nuclear magnetic resonance spectrum is compared with the proton nuclear magnetic resonance spectrum of crystal form A, and there is no obvious chemical shift offset, which determines that the crystal form is a cocrystal, wherein the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to apple acid is 1:1. Example 30 : Preparation of 6-(((2,6 -dimethylpyrimidin -4- yl ) amino )-N- ethoxy -4-((2- methoxy -3-( pyrimidin -2- yl ) phenyl ) amino ) nicotinamide hydrochloride Type A

29.2 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, 1.0 mL of 4-methyl-2-pentanone and 60 μL of 1 mol/L hydrochloric acid ethanol solution were added, and the suspension was suspended and stirred at 25 ^° C for 2 days. The suspension was centrifuged and the solid was collected and simmered at 25 ^{° C.} C and vacuum dried for 24 hours to obtain a sample. The obtained sample was subjected to XRPD test and proton nuclear magnetic resonance analysis, and its X-ray powder diffraction pattern was shown in Figure 62, and its proton nuclear magnetic resonance spectrum was shown in Figure 63. Figure 63 shows that the crystal contains hydrochloric acid, and the proton nuclear magnetic resonance spectrum has an obvious chemical shift offset compared with the proton nuclear magnetic resonance spectrum of the E crystal form, and it is judged that the crystal form is a hydrochloride crystal, wherein the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to hydrochloric acid is 1:1. Example 31 : Preparation of 6-(((2,6 -dimethylpyrimidin -4- yl ) amino )-N- ethoxy -4-((2- methoxy -3-( pyrimidin -2- yl ) phenyl ) amino ) nicotinamide hydrochloride Type B

29.2 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 4 mL EP tube, 1.0 mL of ethyl acetate and 60 μL of 1 mol/L hydrochloric acid ethanol solution were added, and the suspension was stirred at 25 ^° C for 2 days. The suspension was centrifuged and the solid was collected and heated at 40 ^°C . C and vacuum dried for 24 hours to obtain a sample. The obtained sample was subjected to XRPD test and proton nuclear magnetic resonance analysis, and its X-ray powder diffraction pattern was shown in Figure 64, and its proton nuclear magnetic resonance spectrum was shown in Figure 65. Figure 65 shows that its proton nuclear magnetic resonance spectrum indicates that the crystal contains hydrochloric acid, and the proton nuclear magnetic resonance spectrum has an obvious chemical shift offset compared with the proton nuclear magnetic resonance spectrum of the E crystal form, and it is judged that the crystal form is a salt-forming crystal, wherein the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to hydrochloric acid is 1:1. Example 32 : Preparation of Type A Cocrystals of 6-(((2,6 -dimethylpyrimidin -4- yl ) amino )-N- ethoxy -4-((2- methoxy -3-( pyrimidin -2- yl ) phenyl ) amino ) nicotinamide with Glycolic Acid

28.2 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 10 mL EP tube, 4.8 μL of glycolic acid and 0.5 mL of methanol were added, and the suspension was stirred at 25 ^° C for 2 days. The suspension was centrifuged and the solid was collected and simmered at 25 ^°C . C and vacuum dried for 24 hours to obtain a sample. The obtained sample was directly subjected to XRPD test and proton nuclear magnetic resonance analysis, and its X-ray powder diffraction pattern was shown in Figure 66, and its proton nuclear magnetic resonance spectrum was shown in Figure 67. Figure 67 shows that its proton nuclear magnetic resonance spectrum shows that the crystal contains glycolic acid, and the proton nuclear magnetic resonance spectrum is compared with the proton nuclear magnetic resonance spectrum of the E crystal form. There is no obvious chemical shift offset, and the crystal form is judged to be a cocrystal, wherein the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to glycolic acid is 1:1. Example 33 : Preparation of Type B Cocrystal of 6-(((2,6 -dimethylpyrimidin -4- yl ) amino )-N- ethoxy -4-((2- methoxy -3-( pyrimidin -2- yl ) phenyl ) amino ) nicotinamide with Glycolic Acid

28.3 mg of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide was placed in a 10 mL EP tube, 4.9 μL of glycolic acid and 1.0 mL of 4-methyl-2-pentanone were added, and the suspension was stirred at 25 ^° C for 2 days. The suspension was separated by centrifugation, and the solid was collected and heated at 25 ^{° C.} C for 24 hours to obtain a sample. The obtained sample was subjected to XRPD test and proton nuclear magnetic resonance analysis, and its X-ray powder diffraction pattern was shown in Figure 68, and its proton nuclear magnetic resonance spectrum was shown in Figure 69. Figure 69 shows that the crystal contains glycolic acid, and the proton nuclear magnetic resonance spectrum has no obvious chemical shift compared with the proton nuclear magnetic resonance spectrum of the E crystal form, and it is judged that the crystal form is a cocrystal, in which the ratio of 6-(((2,6-dimethylpyrimidin-4-yl)amino)-N-ethoxy-4-((2-methoxy-3-(pyrimidin-2-yl)phenyl)amino)nicotinamide to glycolic acid is 1:1. Example 34 : Thermodynamic stability of non-solventized crystal form E

Take a certain quality of methanol-solventized crystal form A, add 1.0 mL of acetonitrile or 1.0 mL of methyl tert-butyl ether (MTBE), stir at different temperatures to form a saturated solution, then add an equal amount of non-solventized crystal form E and non-solventized crystal form AH to the saturated solution, suspend and stir at the selected specific temperature for 6 days, centrifuge to obtain the solid, and use XRPD to determine its crystal form again. The results are shown in Table 1, and the XRPD comparison chart after stirring is shown in Figure 70. Table 1 Experiment number Amount of Form E (mg) Amount of crystal form AH (mg) Solvent Volume (mL) Temperature ( ^o C) result 1 5.6 5.8 Acetonitrile 1.0 10 Crystalline Form E 2 5.5 5.5 Acetonitrile 1.0 Room temperature Crystalline Form E 3 5.3 5.0 Acetonitrile 1.0 60 Crystalline Form E 4 5.9 5.1 Methyl tert-butyl ether 1.0 10 Crystalline Form E 5 5.3 6.0 Methyl tert-butyl ether 1.0 Room temperature Crystalline Form E 6 5.4 5.3 Methyl tert-butyl ether 1.0 45 Crystalline Form E

The results show that, under the conditions tested, Form E has higher stability than Forms AH. Example 35 : Hygroscopicity of Non-solventized Form E

Weigh 15-20 mg of the non-solventized crystalline form E of the present invention, and use a dynamic moisture sorption and desorption (DVS) instrument to determine its hygroscopicity. The test adopts a gradient mode, and cycles once under the condition of humidity change of 50%-95%-0%-50%. The humidity change of each gradient in the range of 0% to 90% is 10%, and the gradient end point is judged by dm/dt method, and the gradient end point is dm/dt less than 0.002% and maintained for 10 minutes. Record the quality changes at each humidity, and the corresponding quality changes are shown in Figure 71. After the test is completed, the sample is analyzed by XRPD, and its XRPD comparison diagram is shown in Figure 72.

From the DVS test, it can be seen that Form E is non-hygroscopic. Its XRPD results show that the non-solubilized Form E has no crystal form transformation before and after the DVS test. Example 36 : Hygroscopicity of non-solubilized Form AH

Weigh 15-20 mg of the non-solventized crystalline form AH of the present invention, and use a dynamic moisture sorption and desorption (DVS) instrument to determine its hygroscopicity. The test adopts a gradient mode, and cycles once under the condition of humidity change of 50%-95%-0%-50%. The humidity change of each gradient in the range of 0% to 90% is 10%, and the gradient end point is judged by dm/dt method, and the gradient end point is dm/dt less than 0.002% and maintained for 10 minutes. Record the quality changes at each humidity, and the corresponding quality changes are shown in Figure 73. After the test is completed, the sample is analyzed by XRPD, and its XRPD comparison diagram is shown in Figure 74.

From the DVS test, it can be seen that the crystal form AH is hygroscopic. Its XRPD results show that the non-solventized crystal form AH does not undergo crystal form transformation before and after the DVS test. Example 37 : Hygroscopicity of the maleate crystal form A of the compound of formula ( I )

Weigh 15-20 mg of the maleate crystal form Type A of the compound of formula (I) and use a dynamic moisture sorption (DVS) instrument to determine its hygroscopicity. The test adopts a gradient mode and cycles once under the condition of humidity change of 50%-95%-0%-50%. The humidity change of each gradient in the range of 0% to 90% is 10%. The end point of the gradient is judged by the dm/dt method, and the end point of the gradient is when dm/dt is less than 0.002% and maintained for 10 minutes. Record the quality changes at each humidity, and the corresponding quality changes are shown in Figure 75. After the test is completed, the sample is analyzed by XRPD, and its XRPD comparison diagram is shown in Figure 76.

From the DVS test, it can be seen that the maleate crystal form A of the compound of formula (I) is extremely hygroscopic. Its XRPD results show that the maleate crystal form A of the compound of formula (I) does not undergo a crystal form transformation before and after the DVS test. Example 38 : Hygroscopicity of the citric acid cocrystal form A of the compound of formula ( I )

Weigh 15-20 mg of the citric acid cocrystal Type A of the compound of formula (I) and use a dynamic moisture sorption/desorption (DVS) instrument to determine its hygroscopicity. The test adopts a gradient mode and cycles once under the condition of humidity change of 50%-95%-0%-50%. The humidity change of each gradient in the range of 0% to 90% is 10%. The end point of the gradient is judged by the dm/dt method, and the end point of the gradient is when dm/dt is less than 0.002% and maintained for 10 minutes. Record the quality changes at each humidity, and the corresponding quality changes are shown in Figure 77. After the test is completed, the sample is analyzed by XRPD, and its XRPD comparison diagram is shown in Figure 78.

From the DVS test, it can be seen that the citric acid cocrystal of the compound of formula (I) Type A is almost non-hygroscopic. Its XRPD results show that the citric acid cocrystal of the compound of formula (I) Type A does not undergo a crystal transformation before and after the DVS test. Example 39 : Hygroscopicity of the apple acid cocrystal of the compound of formula ( I ) Type A

Weigh 15-20 mg of apple acid cocrystal Type A of the compound of formula (I) and use a dynamic water sorption/desorption (DVS) instrument to determine its hygroscopicity. The test adopts a gradient mode and cycles once under the condition of humidity change of 50%-95%-0%-50%. The humidity change of each gradient in the range of 0% to 90% is 10%. The end point of the gradient is judged by the dm/dt method, and the end point of the gradient is when dm/dt is less than 0.002% and maintained for 10 minutes. Record the quality changes at each humidity, and the corresponding quality changes are shown in Figure 79. After the test is completed, the sample is analyzed by XRPD, and its XRPD comparison diagram is shown in Figure 80.

From the DVS test, it can be seen that the apple acid cocrystal crystal form A of the compound of formula (I) is slightly hygroscopic, and its XRPD results show that the apple acid cocrystal crystal form A of the compound of formula (I) does not undergo a crystal form transformation before and after the DVS test. Example 40 : Stability of the non-solventized crystal form E

About 15 mg of the insolvent-free crystalline form E of the present invention was weighed and placed in a weighing bottle, which was then opened and placed under high temperature (60 ºC), high humidity (25 ºC/92.5% RH), light (25 ºC/4500 Lux), acceleration (40 ºC/75% RH) and room temperature (25 ^o C/60%RH), and samples were taken at specific time points for XRPD characterization. The results are shown in Table 2, and the XRPD comparison diagram is shown in Figure 81. Table 2 Starting crystal form Placement conditions Placement time 15 days results 30-day results 90 Day Results Crystalline Form E High temperature 60 ^o C No change in crystal form No change in crystal form No change in crystal form Crystalline Form E High humidity 25 ^o C/92.5% RH No change in crystal form No change in crystal form No change in crystal form Crystalline Form E Lighting: 25 ^° C/4500 Lux New peaks appear at 7.68° and 13.04° New peaks appear at 7.68° and 13.04° No change in crystal form Crystalline Form E Accelerated 40 ^o C/75%RH No change in crystal form No change in crystal form No change in crystal form Crystalline Form E 25 ^° C/60%RH No change in crystal form No change in crystal form No change in crystal form

According to the above experimental results, the non-solventized crystalline form E remains stable under high temperature, high humidity, accelerated and room temperature conditions and has high stability. Example 41 : Stability of non-solventized crystalline form AH

About 15 mg of the non-solventized crystalline form AH of the present invention was weighed and placed in a weighing bottle, which was then opened and placed under high temperature (60 ºC), high humidity (25 ºC/92.5% RH), light (25 ºC/4500 Lux), acceleration (40 ºC/75% RH) and room temperature (25 ^o C/60%RH), and samples were taken at specific time points for XRPD characterization. The results are shown in Table 3, and the XRPD comparison diagram is shown in Figure 82. Table 3 Starting crystal form Placement conditions Placement time 15 days results 30-day results 90 Day Results Crystal form AH High temperature 60 ^o C No change in crystal form No change in crystal form No change in crystal form Crystal form AH High humidity 25 ^o C/92.5% RH No change in crystal form No change in crystal form No change in crystal form Crystal form AH Lighting: 25 ^° C/4500 Lux No change in crystal form No change in crystal form No change in crystal form Crystal form AH Accelerated 40 ^o C/75%RH No change in crystal form No change in crystal form No change in crystal form Crystal form AH 25 ^° C/60%RH No change in crystal form No change in crystal form No change in crystal form

According to the above experimental results, the non-solventized crystalline form AH remains stable under high temperature, high humidity, light, accelerated and room temperature conditions and has high stability. Example 42 : Stability of the maleate crystalline form Type A of the compound of formula ( I )

About 15 mg of the maleate crystal form A of the compound of formula (I) of the present invention was weighed and placed in a weighing bottle, which was opened and placed under high temperature (60 ºC), high humidity (25 ºC/92.5% RH), light (25 ºC/4500 Lux), acceleration (40 ºC/75% RH) and room temperature (25 ^o C/60%RH), and samples were taken at specific time points for XRPD characterization. The results are shown in Table 4, and the XRPD comparison diagram is shown in Figure 83. Table 4 Starting crystal form Placement conditions Placement time result Maleate Crystalline Type A High temperature 60 ^o C 7 days No change in crystal form Maleate Crystalline Type A High humidity 25 ^o C/92.5% RH 7 days No change in crystal form Maleate Crystalline Type A Lighting: 25 ^° C/4500 Lux 7 days The crystal form did not change, but the sample color changed from white to yellow. Maleate Crystalline Type A Accelerated 40 ^o C/75%RH 7 days No change in crystal form Maleate Crystalline Type A 25 ^° C/60%RH 7 days No change in crystal form

According to the above experimental results, the maleate crystal form Type A remains stable under high temperature, high humidity, accelerated and room temperature conditions and has high stability. Example 43 : Stability of the citric acid cocrystal form Type A of the compound of formula ( I )

About 15 mg of the citrate cocrystal Type A of the compound of formula (I) of the present invention was weighed and placed in a weighing bottle, which was then opened and placed under high temperature (60 ºC), high humidity (25 ºC/92.5% RH), light (25 ºC/4500 Lux), acceleration (40 ºC/75% RH) and room temperature (25 ^o C/60%RH), and samples were taken at specific time points for XRPD characterization. The results are shown in Table 5, and the XRPD comparison diagram is shown in Figure 84. Table 5 Starting crystal form Placement conditions Placement time result Citrate eutectic type A High temperature 60 ^o C 7 days No change in crystal form Citrate eutectic type A High humidity 25 ^o C/92.5% RH 7 days No change in crystal form Citrate eutectic type A Lighting: 25 ^° C/4500 Lux 7 days The crystal form did not change, but the sample color changed from white to yellow. Citrate eutectic type A Accelerated 40 ^o C/75%RH 7 days No change in crystal form Citrate eutectic type A 25 ^° C/60%RH 7 days No change in crystal form

According to the above experimental results, the citrate eutectic crystal form Type A remains stable under high temperature, high humidity, accelerated and room temperature conditions and has high stability. Example 44 : Stability of the apple acid eutectic crystal form Type A of the compound of formula ( I )

About 15 mg of the apple acid salt of the compound of formula (I) of the present invention, the crystal form Type A, was weighed and placed in a weighing bottle, and then placed open at high temperature (60 ºC), high humidity (25 ºC/92.5% RH), light (25 ºC/4500 Lux), acceleration (40 ºC/75% RH) and room temperature (25 ^o C/60%RH), and samples were taken at specific time points for XRPD characterization. The results are shown in Table 6, and the XRPD comparison diagram is shown in Figure 85. Table 6 Starting crystal form Placement conditions Placement time result Apple acid salt eutectic crystal type A High temperature 60 ^o C 7 days No change in crystal form Apple acid salt eutectic crystal type A High humidity 25 ^o C/92.5% RH 7 days No change in crystal form Apple acid salt eutectic crystal type A Lighting: 25 ^° C/4500 Lux 7 days The crystal form did not change, but the sample color changed from white to yellow. Apple acid salt eutectic crystal type A Accelerated 40 ^o C/75%RH 7 days No change in crystal form Apple acid salt eutectic crystal type A 25 ^° C/60%RH 7 days No change in crystal form

According to the above experimental results, the apple phosphate eutectic Type A remains stable under high temperature, high humidity, accelerated and room temperature conditions and has high stability.

without

Figure 1 is an XPRD spectrum of methanol-solventized crystals A of the compound represented by formula (I). Figure 2 is a proton nuclear magnetic resonance spectrum of methanol-solventized crystals A of the compound represented by formula (I). Figure 3 is an XPRD spectrum of hydrated crystals AA of the compound represented by formula (I). Figure 4 is a proton nuclear magnetic resonance spectrum of hydrated crystals AA of the compound represented by formula (I). Figure 5 is an XPRD spectrum of methanol-solventized crystals AE of the compound represented by formula (I). Figure 6 is a proton nuclear magnetic resonance spectrum of methanol-solventized crystals AE of the compound represented by formula (I). Figure 7 is an XPRD spectrum of non-solventized crystals AH of the compound represented by formula (I). Figure 8 is a proton nuclear magnetic resonance spectrum of non-solventized crystals AH of the compound represented by formula (I). Figure 9 is a differential scanning calorimetric analysis curve of the non-solventized crystals AH of the compound represented by formula (I). Figure 10 is a thermogravimetric analysis curve of the non-solventized crystals AH of the compound represented by formula (I). Figure 11 is an XPRD spectrum of the non-solventized crystals E (E crystal form) of the compound represented by formula (I). Figure 12 is a proton nuclear magnetic resonance spectrum of the non-solventized crystals E (E crystal form) of the compound represented by formula (I). Figure 13 is a differential scanning calorimetric analysis curve of the non-solventized crystals E (E crystal form) of the compound represented by formula (I). Figure 14 is a thermogravimetric analysis curve of the non-solventized crystals E (E crystal form) of the compound represented by formula (I). Figure 15 is an X-ray single crystal diffraction spectrum of non-solventized crystal E (E crystal form) of the compound represented by formula (I). Figure 16 is an XPRD spectrum of formic acid solvated crystal F of the compound represented by formula (I). Figure 17 is a proton nuclear magnetic resonance spectrum of formic acid solvated crystal F of the compound represented by formula (I). Figure 18 is an XPRD spectrum of formic acid solvated crystal O of the compound represented by formula (I). Figure 19 is a proton nuclear magnetic resonance spectrum of formic acid solvated crystal O of the compound represented by formula (I). Figure 20 is an XPRD spectrum of hydrated crystal T of the compound represented by formula (I). Figure 21 is a proton nuclear magnetic resonance spectrum of hydrated crystal T of the compound represented by formula (I). Figure 22 is an XPRD spectrum of hydrated crystal V of the compound represented by formula (I). Figure 23 is a proton nuclear magnetic resonance spectrum of the hydrate crystal V of the compound represented by formula (I). Figure 24 is an XPRD spectrum of the formic acid solvent crystal AF of the compound represented by formula (I). Figure 25 is a proton nuclear magnetic resonance spectrum of the formic acid solvent crystal AF of the compound represented by formula (I). Figure 26 is an XPRD spectrum of the hydrate crystal L of the compound represented by formula (I). Figure 27 is a proton nuclear magnetic resonance spectrum of the hydrate crystal L of the compound represented by formula (I). Figure 28 is an XPRD spectrum of the ethanol solvent crystal R of the compound represented by formula (I). Figure 29 is a proton nuclear magnetic resonance spectrum of the ethanol solvent crystal R of the compound represented by formula (I). Figure 30 is an XPRD spectrum of the oxalic acid eutectic crystal Type A of the compound represented by formula (I). Figure 31 is a proton nuclear magnetic resonance spectrum of Type A oxalic acid eutectic crystals of the compound represented by formula (I). Figure 32 is an XPRD spectrum of Type B oxalic acid eutectic crystals of the compound represented by formula (I). Figure 33 is a proton nuclear magnetic resonance spectrum of Type B oxalic acid eutectic crystals of the compound represented by formula (I). Figure 34 is an XPRD spectrum of Type A p-toluenesulfonate crystals of the compound represented by formula (I). Figure 35 is a proton nuclear magnetic resonance spectrum of Type A p-toluenesulfonate crystals of the compound represented by formula (I). Figure 36 is an XPRD spectrum of Type B p-toluenesulfonate crystals of the compound represented by formula (I). Figure 37 is a proton nuclear magnetic resonance spectrum of Type B p-toluenesulfonate crystals of the compound represented by formula (I). Figure 38 is an XPRD spectrum of Type C p-toluenesulfonate crystals of the compound represented by formula (I). Figure 39 is a proton nuclear magnetic resonance spectrum of Type C p-toluenesulfonate crystals of the compound represented by formula (I). Figure 40 is an XPRD spectrum of Type B fumaric acid eutectic crystals of the compound represented by formula (I). Figure 41 is a proton nuclear magnetic resonance spectrum of Type B fumaric acid eutectic crystals of the compound represented by formula (I). Figure 42 is an XPRD spectrum of Type C fumaric acid eutectic crystals of the compound represented by formula (I). Figure 43 is a proton nuclear magnetic resonance spectrum of Type C fumaric acid eutectic crystals of the compound represented by formula (I). Figure 44 is an XPRD spectrum of Type A methanesulfonate crystals of the compound represented by formula (I). Figure 45 is a proton nuclear magnetic resonance spectrum of Type A crystals of the methanesulfonate salt of the compound represented by formula (I). Figure 46 is an XPRD spectrum of Type B crystals of the methanesulfonate salt of the compound represented by formula (I). Figure 47 is a proton nuclear magnetic resonance spectrum of Type B crystals of the methanesulfonate salt of the compound represented by formula (I). Figure 48 is an XPRD spectrum of Type C crystals of the methanesulfonate salt of the compound represented by formula (I). Figure 49 is a proton nuclear magnetic resonance spectrum of Type C crystals of the methanesulfonate salt of the compound represented by formula (I). Figure 50 is an XPRD spectrum of Type A crystals of the potassium salt of the compound represented by formula (I). Figure 51 is a proton nuclear magnetic resonance spectrum of Type A crystals of the potassium salt of the compound represented by formula (I). Figure 52 is an XPRD spectrum of Type A maleate crystals of the compound represented by formula (I). Figure 53 is a proton nuclear magnetic resonance spectrum of Type A maleate crystals of the compound represented by formula (I). Figure 54 is an XPRD spectrum of Type B maleate crystals of the compound represented by formula (I). Figure 55 is a proton nuclear magnetic resonance spectrum of Type B maleate crystals of the compound represented by formula (I). Figure 56 is an XPRD spectrum of Type B sodium salt crystals of the compound represented by formula (I). Figure 57 is a proton nuclear magnetic resonance spectrum of Type B sodium salt crystals of the compound represented by formula (I). Figure 58 is an XPRD spectrum of Type A citrate eutectic of the compound represented by formula (I). Figure 59 is a proton nuclear magnetic resonance spectrum of Type A citrate cocrystal of the compound represented by formula (I). Figure 60 is an XPRD spectrum of Type A apple acid cocrystal crystal of the compound represented by formula (I). Figure 61 is a proton nuclear magnetic resonance spectrum of Type A apple acid cocrystal crystal of the compound represented by formula (I). Figure 62 is an XPRD spectrum of Type A hydrochloride of the compound represented by formula (I). Figure 63 is a proton nuclear magnetic resonance spectrum of Type A hydrochloride of the compound represented by formula (I). Figure 64 is an XPRD spectrum of Type B hydrochloride of the compound represented by formula (I). Figure 65 is a proton nuclear magnetic resonance spectrum of Type B hydrochloride of the compound represented by formula (I). Figure 66 is an XPRD spectrum of Type A eutectic crystals of the compound represented by formula (I). Figure 67 is a proton nuclear magnetic resonance spectrum of Type A eutectic crystals of the compound represented by formula (I). Figure 68 is an XPRD spectrum of Type B eutectic crystals of the compound represented by formula (I). Figure 69 is a proton nuclear magnetic resonance spectrum of Type B eutectic crystals of the compound represented by formula (I). Figure 70 is an XRPD spectrum of the solid obtained in Example 34. Figure 71 is a quality change of the sample of the non-solventized crystal form E of the compound represented by formula (I) in Example 35 under different humidity conditions in the DVS experiment. Figure 72 is an XRPD spectrum of the sample of the non-solventized crystal form E of the compound represented by formula (I) in Example 35 after the DVS experiment. Figure 73 shows the quality change of the sample of the non-solventized crystalline form AH of the compound of formula (I) in Example 36 under different humidity conditions in the DVS experiment. Figure 74 shows the XRPD spectrum of the sample of the non-solventized crystalline form AH of the compound of formula (I) in Example 36 after the DVS experiment. Figure 75 shows the quality change of the sample of the maleate crystalline form Type A of the compound of formula (I) in Example 37 under different humidity conditions in the DVS experiment. Figure 76 shows the XRPD spectrum of the sample of the maleate crystalline form Type A of the compound of formula (I) in Example 37 after the DVS experiment. Figure 77 shows the quality change of the sample of the citric acid cocrystal crystalline form Type A of the compound of formula (I) in Example 38 under different humidity conditions in the DVS experiment. Figure 78 is an XRPD spectrum of the sample of the citric acid cocrystal type A of the compound of formula (I) in Example 38 after DVS experiment. Figure 79 is the quality change of the sample of the apple acid cocrystal type A of the compound of formula (I) in Example 39 under different humidity conditions in the DVS experiment. Figure 80 is an XRPD spectrum of the sample of the apple acid cocrystal type A of the compound of formula (I) in Example 39 after DVS experiment. Figure 81 is an XRPD spectrum of the sample of the non-solventized crystal type E of the compound of formula (I) in Example 40 after stability test under different conditions. Figure 82 is an XRPD spectrum of the sample of the non-solventized crystal type AH of the compound of formula (I) in Example 41 after stability test under different conditions. Figure 83 is an XRPD spectrum of samples of the maleate crystal form Type A of the compound of formula (I) in Example 42 after stability tests under different conditions. Figure 84 is an XRPD spectrum of samples of the citric acid cocrystal crystal form Type A of the compound of formula (I) in Example 43 after stability tests under different conditions. Figure 85 is an XRPD spectrum of samples of the apple acid cocrystal crystal form Type A of the compound of formula (I) in Example 44 after stability tests under different conditions.

Claims (50)

An unsolvated crystal, a hydrate crystal, a solvated crystal, a eutectic crystal, or a salt crystal of a compound represented by formula (I), characterized in that: (I); The non-solubilized crystals are selected from: non-solubilized crystals AH, whose X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 7.65 ^° , 11.26 ^° , 11.43 ^° , 15.07 ^° , 15.32 ^° , 19.07 ^° , 20.12 ^° and 20.78 ^° ; non-solubilized crystals E, whose X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 7.19 ^° , 9.59 ^° , 14.46°, 18.15 ^° , 20.41 ^° , 23.44 ^° , 23.67 ^° , 24.01 ^° , 24.34 ^° and ^{24.60° ;} The hydrate crystals are selected from: The X-ray powder diffraction pattern of hydrate crystal AA has characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 7.85 ^° , 10.35 ^° , 12.74 ^° , 14.95 ^° , 17.94 ^° , 18.05 ^° , 19.01 ^° , 20.90 ^° and 27.26 ^° ; the X-ray powder diffraction pattern of hydrate crystal T has characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 4.31 ^° , 6.09 ^° , 6.82 ^° , 11.05 ^° , 18.49 ^° , 19.74 ^° , 24.32 ^° and 26.78 ^° ; the X-ray powder diffraction pattern of hydrate crystal V has characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 6.34 ^° , 7.48 ^° , 7.95 ^° , 10.27 ^° , 12.97 ^° , 17.90 ^° , 20.71 ^° and 23.98 ^° ; hydrate crystal L, whose X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 6.69 ^° , 8.02 ^° , 9.93 ^° , 14.23 ^° , 16.13 ^° , 16.29 ^° , 18.13 ^° , 19.18 ^° and 24.32 ^° ; the solvated crystal is selected from: methanol solvate crystal A, wherein the ratio of the compound represented by formula (I) to methanol is 1:1; its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 4.56 ^° , 9.16 ^° , 9.34 ^° , 12.91 ^° , 13.78 ^° , 14.66 ^° , 15.25 ^° , 18.52 ^° and 23.12 ^° ; methanol solvent crystal AE, wherein the ratio of the compound represented by formula (I) to methanol is 1:0.4; its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 9.08 ^° , 9.63 ^° , 13.11 ^{° , 13.70°, 14.80°, 15.29°, 17.88° , 18.78 ° ,} 22.94 ^° and 23.46 ^° ; formic acid solvent crystal F, wherein the ratio of the compound represented by formula (I) to formic acid is 1:1, its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 4.96 ^° , 5.30 ^° , 7.25 ^° , 8.44 ^° , 12.14 ^° , 15.04 ^° , 15.83 ^° , 19.47 ^° and 20.11 ^° ; formic acid solvated crystal O, wherein the ratio of the compound represented by formula (I) to formic acid is 1:1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 5.30 ^° , 10.68 ^° , 11.72 ^° , 15.25 ^° , 16.09 ^° , 17.99 ^° , 20.50 ^° , 22.30 ^° , 25.78 ^° and 26.57 ^° ; formic acid solvated crystal AF, wherein the ratio of the compound represented by formula (I) to formic acid is 1:1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles (±0.2 ^°). ) has characteristic diffraction peaks: 6.19 ^o , 7.48 ^o , 8.32 ^o , 12.49 ^o , 13.46 ^o and 14.76 ^o ; Ethanol solvated crystal R, wherein the ratio of the compound represented by formula (I) to ethanol is 1:0.3, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles (±0.2 ^o ): 8.37 ^o , 12.51 ^o , 16.14 ^o , 17.56 ^o , 17.69 ^o , 18.36 ^o , 18.68 ^o , 19.45 ^o , 21.71 ^o , 23.01 ^o and 24.14 ^o ; The co-crystal is selected from: Oxalic acid co-crystal Type A, wherein the ratio of the compound represented by formula (I) to oxalic acid is 1:1; its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles (±0.2 ^o ) has characteristic diffraction peaks: 6.07 ^o , 11.01 ^o , 12.23 ^o , 12.80 ^o , 14.28 ^o , 16.93 ^o and 21.76 ^o ; Oxalic acid eutectic crystal Type B, the ratio of the compound of formula (I) to oxalic acid is 1:1; its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles (±0.2 ^o ): 6.01 ^o , 8.19 ^o , 11.55 ^o , 12.34 ^o , 13.79 ^o , 17.36 ^o , 18.14 ^o , 20.56 ^o , 23.27 ^o , 23.94 ^o and 25.24 ^o ; Fumaric acid eutectic crystal Type B, the ratio of the compound of formula (I) to fumaric acid is 1:1, its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles (±0.2 ^o ) has characteristic diffraction peaks: 5.18 ^o , 6.43 ^o , 10.93 ^o , 11.46 ^o , 12.39 ^o , 15.96 ^o , 16.22 ^o , 19.28 ^o and 22.09 ^o ; Fumaric acid eutectic crystal Type C, the ratio of the compound of formula (I) to fumaric acid is 1:1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles (±0.2 ^o ): 7.14 ^o , 7.49 ^o , 10.87 ^o , 12.17 ^o , 17.38 ^o , 19.81 ^o , 20.63 ^o , 21.58 ^o , 23.27 ^o , 24.38 ^o and 25.39 ^o ; Citric acid eutectic crystal Type A, the ratio of the compound of formula (I) to citric acid is 1: 1, its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 5.56 ^° , 6.52 ^° , 9.85 ^° , 14.27 ^° , 14.62 ^° , 16.60 ^° , 17.73 ^° , 19.71 ^° , 19.86 ^° , 24.36 ^° and 26.42 ^° ; apple acid cocrystal Type A, the ratio of the compound of formula (I) to apple acid is 1:1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 7.14 ^° , 8.77 ^° , 8.99 ^° , 9.90 ^° , 11.59 ^° , 11.84 ^° , 17.27 ^° , 19.91 ^° , 20.22 ^° , 21.09° ^o , 23.74 ^o and 25.22 ^o ; Ethanol acid cocrystal Type A, the ratio of the compound of formula (I) to ethanol is 1: 1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles (±0.2 ^o ): 5.61 ^o , 6.83 ^o , 8.27 ^o , 11.25 ^o , 13.73 ^o , 14.63 ^o , 16.94 ^o , 19.79 ^o and 23.23 ^o ; Ethanol acid cocrystal Type B, the ratio of the compound of formula (I) to ethanol is 1: 1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles (±0.2 ^o ): 5.44 ^o , 6.70 ^o , 8.29 ^o , 10.96 ^o , 13.50 ^o , 14.25 ^o , 16.48 ^o , 20.83 ^o and 25.06 ^o ; The salt type crystal is selected from: p-toluenesulfonate crystal Type A, the ratio of the compound represented by formula (I) to p-toluenesulfonic acid is 1:1; its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles (±0.2 ^o ): 7.41 ^o , 9.57 ^o , 9.92 ^o , 16.06 ^o , 16.94 ^o , 19.70 ^o , 20.44 ^o , 22.07 ^o and 26.24 ^o ; p-toluenesulfonate crystal Type B, the ratio of the compound represented by formula (I) to p-toluenesulfonic acid is 1:1; its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles (±0.2 ^o ): 6.35 ^o , 6.93 ^o , 7.63 ^o , 14.59 ^o , 16.79 o ^o and 20.79 ^o ; p-toluenesulfonate crystals Type C, the ratio of the compound represented by formula (I) to p-toluenesulfonic acid is 1:1; its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles (±0.2 ^o ): 5.19 ^o , 6.87 ^o , 10.06 ^o , 13.79 ^o , 16.62 ^o , 16.93 ^o , 20.44 ^o , 24.53 ^o and 26.12 ^o ; methanesulfonate crystals Type A, the ratio of the compound represented by formula (I) to methanesulfonic acid is 1:1; its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles (±0.2 ^o ): 8.09 ^o , 9.60 ^o , 11.06 ^o , 12.57 ^o , 14.33 ^o , 14.55 ^o , 16.93 ^o , 19.32 ^o , 19.64 ^o , 20.19 ^o , 20.31 ^o , 21.05 ^o and 26.42 ^o ; Type B mesylate crystals, the ratio of the compound represented by formula (I) to methanesulfonic acid is 1: 1.2; its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles (±0.2 ^o ): 5.74 ^o , 5.89 ^o , 11.53 ^o , 11.93 o , 12.47 ^o , 12.90 ^o , 14.06 ^o , 15.01 ^o , 17.14 ^o and ^{25.52 o ;} Type C mesylate crystals, the ratio of the compound represented by formula (I) to p-toluenesulfonic acid is 1: 1; its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles (±0.2 ^o ): 5.32 ^o , 8.45 ^o , 11.84 ^o , 17.01 ^o , 18.49 ^o , 21.30 ^o and 22.98 ^o ; Potassium salt crystal Type A, which has the structure ; Its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 5.74 ^° , 6.68 ^° , 7.96 ^° , 13.54 ^° , 14.04 ^° , 17.78 ^° , 20.14 ^° and 23.29 ^° ; Maleate salt crystals Type A, the ratio of the compound represented by formula (I) to maleic acid is 1:1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 4.26 ^° , 4.76 ^° , 7.08 ^° , 7.96 ^° , 8.54 ^° , 9.53 ^° , 10.18 ^° , 10.93 ^° , 14.34 ^° , 15.03 ^° , 15.99 ^° and 20.50 ^° ; Maleate salt crystals Type B, the ratio of the compound represented by formula (I) to maleic acid is 1:1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 4.34 ^° , 4.79 ^° , 5.27 ^° , 7.20 ^° , 7.86 ^° , 10.22 ^° , 10.56 ^° , 11.08 ^° , 14.73 ^° , 15.20 ^° , 16.14 ^° and 20.50 ^° ; Sodium salt crystal Type B, which has the structure ; Its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 6.01 ^° , 6.61 ^° , 7.94 ^° , 11.88 ^° , 12.48 ^° , 13.10 ^° , 13.70 ^° , 18.31 ^° , 19.98 ^° , 21.19 ^° , 22.35 ^° , 25.36 ^° and 26.27 ^° ; Hydrochloride crystals Type A, the ratio of the compound represented by formula (I) to hydrochloric acid is 1:1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 5.90 ^° , 7.42 ^° , 7.74 ^° , 10.96 ^° , 14.07 ^° , 14.96 ^° , 18.01 ^° , 25.14° ^o and 26.42 ^o ; hydrochloride crystals Type B, the ratio of the compound represented by formula (I) to hydrochloric acid is 1:1, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles (±0.2 ^o ): 6.48 ^o , 7.20 ^o , 7.90 ^o , 14.16 ^o , 14.48 ^o , 15.68 ^o , 17.31 ^o , 21.76 ^o and 26.53 ^o . The non-solubilized crystals, hydrate crystals, solvated crystals, co-crystal crystals and salt-type crystals as described in claim 1, wherein: the non-solubilized crystals AH of the compound represented by formula (I) have characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ) in its X-ray powder diffraction pattern: 7.65 ^° , 11.26 ^° , 11.43 ^° , 15.07 ^° , 15.32 ^° , 16.60 ^° , 19.07 ^° , 20.12 ^° , 20.78 ^° and 23.02 ^° . The non-solubilized crystals, hydrate crystals, solvated crystals, co-crystal crystals and salt-type crystals as described in claim 1, wherein: the non-solubilized crystals AH of the compound represented by formula (I) have characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ) in its X-ray powder diffraction pattern: 7.65 ^° , 9.47 ^° , 11.26 ^° , 11.43 ^° , 15.07 ^° , 15.32 ^° , 16.31 ^° , 16.60 ^° , 19.07 ^° , 20.12 ^° , 20.78 ^° , 23.02 ^° and 25.77 ^° . The non-solubilized crystals, hydrate crystals, solvated crystals, co-crystal crystals, and salt-type crystals as described in claim 1, wherein: the non-solubilized crystals AH of the compound of formula (I) have characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ) in its X-ray powder diffraction pattern: 7.65 ^° , 8.36 ^° , 9.47 ^° , 9.80 ^° , 11.26 ^° , 11.43 ^° , 11.55 ^° , 11.80 ^° , 12.95 ^° , 13.64 ^° , 14.34 ^° , 14.74 ^° , 15.07 ^° , 15.32 ^° , 15.91 ^° , 16.31 ^° , 16.60 ^° , 16.87 ^° , 18.72 ^° , 19.07 ^° , 19.73 ^° , 20.12 ^o , 20.78 ^o , 21.30 ^o , 21.45 ^o , 21.95 ^o , 22.31 ^o , 23.02 ^o , 23.30 ^o , 23.67 ^o , 23.84 ^o , 24.65 ^o , 25.77 ^o , 26.57 ^o , 26.90 ^o , 28.29 ^o , 28.85 ^o , 29.54 ^o . The non-solubilized crystals, hydrate crystals, solvated crystals, eutectic crystals, and salt-type crystals as described in claim 1, wherein: the non-solubilized crystals AH of the compound represented by formula (I) have an X-ray powder diffraction pattern as shown in Figure 7. The insolubilized crystals, hydrate crystals, solvated crystals, co-crystal crystals and salt-type crystals as described in claim 1, wherein: the insolubilized crystals E of the compound represented by formula (I) have characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ) in its X-ray powder diffraction pattern: 7.19 ^° , 9.59 ^° , 13.64 ^° , 14.46 ^° , 18.15 ^° , 19.19 ^° , 20.41 ^° , 23.44 ^° , 23.67 ^° , 24.01 ^° , 24.34 ^° and 24.60 ^° . The insolubilized crystals, hydrate crystals, solvated crystals, co-crystal crystals and salt-type crystals as described in claim 1, wherein: the insolubilized crystals E of the compound represented by formula (I) have characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ) in its X-ray powder diffraction pattern: 7.19 ^° , 8.93 ^° , 9.59 ^° , 12.72 ^° , 13.64 ^° , 14.46 ^° , 18.15 ^° , 19.19 ^° , 19.96 ^° , 20.41 ^° , 23.44 ^° , 23.67 ^° , 24.01 ^{°, 24.34° ,} 24.60 ^° and 28.60 ^° . The insolubilized crystals, hydrate crystals, solvated crystals, co-crystal crystals, and salt-type crystals as described in claim 1, wherein: the insolubilized crystals E of the compound of formula (I) have characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ) in its X-ray powder diffraction pattern: 7.19 ^° , 8.93 ^° , 9.59 ^° , 10.14 ^° , 10.52 ^° , 11.74 ^° , 12.31 ^° , 12.72 ^° , 13.64 ^° , 14.46 ^° , 15.33 ^° , 15.85 ^° , 16.62°, 17.02 ^° , 18.03 ^° , 18.15 ^° , 18.72 ^° , 19.19 ^° , 19.36 ^° , 19.96 ^° , ^{20.41 °} , 20.90 ^o , 23.44 ^o , 23.67 ^o , 24.01 ^o , 24.34 ^o , 24.60 ^o , 25.69 ^o , 26.66 ^o , 28.60 ^o , 29.19 ^o , 32.08 ^o . The non-solubilized crystals, hydrate crystals, solvated crystals, eutectic crystals, and salt-type crystals as described in claim 1, wherein: the non-solubilized crystals E of the compound represented by formula (I) have an X-ray powder diffraction pattern as shown in Figure 11. The non-solubilized crystals, hydrated crystals, solubilized crystals, eutectic crystals, and salt-type crystals as described in claim 1, wherein: the hydrated crystal AA of the compound represented by formula (I) has an X-ray powder diffraction pattern as shown in FIG3 . The non-solubilized crystals, hydrated crystals, solubilized crystals, eutectic crystals, and salt-type crystals as described in claim 1, wherein: the hydrate crystal T of the compound represented by formula (I) has an X-ray powder diffraction pattern as shown in Figure 20. The non-solubilized crystals, hydrated crystals, solubilized crystals, eutectic crystals, and salt-type crystals as described in claim 1, wherein: the hydrate crystal V of the compound of formula (I) has an X-ray powder diffraction pattern as shown in Figure 22. The non-solubilized crystals, hydrated crystals, solubilized crystals, eutectic crystals, and salt-type crystals as described in claim 1, wherein: the hydrate crystal L of the compound of formula (I) has an X-ray powder diffraction pattern as shown in Figure 26. The non-solvated crystals, hydrate crystals, solvated crystals, eutectic crystals, and salt-type crystals as described in claim 1, wherein: the methanol solvate crystal A of the compound represented by formula (I) has an X-ray powder diffraction pattern as shown in Figure 1. The non-solvated crystals, hydrate crystals, solvated crystals, eutectic crystals, and salt-type crystals as described in claim 1, wherein: the methanol solvate crystals AE of the compound represented by formula (I) have an X-ray powder diffraction pattern as shown in FIG5 . The non-solubilized crystals, hydrate crystals, solvated crystals, eutectic crystals, and salt-type crystals as described in claim 1, wherein: the formic acid solvated crystals F of the compound represented by formula (I) have an X-ray powder diffraction pattern as shown in Figure 16. The non-solubilized crystals, hydrate crystals, solvated crystals, eutectic crystals, and salt-type crystals as described in claim 1, wherein: the formic acid solvated crystal O of the compound represented by formula (I) has an X-ray powder diffraction pattern as shown in Figure 18. The non-solubilized crystals, hydrate crystals, solvated crystals, eutectic crystals, and salt-type crystals as described in claim 1, wherein: the formic acid solvated crystals AF of the compound represented by formula (I) have an X-ray powder diffraction pattern as shown in Figure 24. The non-solvated crystals, hydrate crystals, solvated crystals, eutectic crystals, and salt-type crystals as described in claim 1, wherein: the ethanol solvate crystal R of the compound represented by formula (I) has an X-ray powder diffraction pattern as shown in Figure 28. The non-solubilized crystals, hydrate crystals, solubilized crystals, co-crystal crystals, and salt-type crystals as described in claim 1, wherein: the oxalic acid co-crystal crystals Type A of the compound of formula (I) have an X-ray powder diffraction pattern as shown in Figure 30. The non-solubilized crystals, hydrate crystals, solubilized crystals, eutectic crystals, and salt-type crystals as described in claim 1, wherein: the oxalic acid eutectic crystals Type B of the compound of formula (I) have an X-ray powder diffraction pattern as shown in Figure 32. The non-solubilized crystals, hydrate crystals, solubilized crystals, eutectic crystals, and salt-type crystals as described in claim 1, wherein: the fumaric acid eutectic crystals Type B of the compound of formula (I) have an X-ray powder diffraction pattern as shown in Figure 40. The non-solubilized crystals, hydrated crystals, solubilized crystals, eutectic crystals, and salt-type crystals as described in claim 1, wherein: the fumaric acid eutectic crystal Type C has an X-ray powder diffraction pattern as shown in Figure 42. The non-solubilized crystals, hydrate crystals, solvated crystals, co-crystal crystals, and salt-type crystals as described in claim 1, wherein: the citric acid co-crystal crystals Type A of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 5.56 ^° , 6.52 ^° , 9.85 ^° , 13.20 ^° , 13.46 ^° , 14.27 ^° , 14.62 ^° , 15.78 ^° , 16.60 ^° , 17.73°, 19.71 ^° , 19.86 ^° , 24.36 ^° , 25.16 ^° , and ^{26.42° .} The non-solubilized crystals, hydrated crystals, solvated crystals, co-crystals and salt-type crystals as described in claim 1, wherein: the citric acid co-crystals Type A of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 5.56 ^° , 6.52 ^° , 7.10 ^° , 9.85 ^° , 13.20 ^° , 13.46 ^° , 14.27 ^° , 14.62 ^° , 15.41 ^° , 15.78 ^° , 16.29 ^° , 16.60 ^° , 17.73 ^° , 19.31 ^° , 19.71 ^° , 19.86 ^° , 23.15 ^° , 24.36 ^° , 25.16 ^° and 26.42 ^° . The non-solubilized crystals, hydrated crystals, solvated crystals, co-crystals and salt-type crystals as described in claim 1, wherein: the citric acid co-crystals Type A of the compound of formula (I) has a X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 5.56 ^° , 6.52 ^° , 7.10 ^° , 9.85 ^° , 11.00 ^° , 12.76 ^° , 13.20 ^° , 13.46 ^° , 14.27 ^° , 14.62 ^° , 15.41°, 15.78 ^° , 16.29 ^° , 16.60 ^° , 17.73 ^° , 19.31 ^° , 19.71 ^° , 19.86 ^° , 23.15 ^° , 23.51 ^° , 24.36 ^{° o} , 25.16 ^o , 25.56 ^o , 25.70 ^o , 26.42 ^o , 27.08 ^o , 27.53 ^o , 27.74 ^o , 28.08 ^o , 32.03 ^o . The non-solubilized crystals, hydrated crystals, solvated crystals, co-crystal crystals and salt-type crystals as described in claim 1, wherein: the citric acid co-crystal crystal Type A of the compound of formula (I) has an X-ray powder diffraction pattern as shown in Figure 58. The non-solubilized crystals, hydrate crystals, solvated crystals, co-crystal crystals, and salt-type crystals as described in claim 1, wherein: the apple acid co-crystal crystal Type A of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 7.14 ^° , 8.77 ^° , 8.99 ^° , 9.90 ^° , 11.59 ^° , 11.84 ^° , 17.27 ^° , 18.02 ^° , 19.21 ^° , 19.91 ^{°, 20.22° ,} 21.09 ^° , 22.98 ^° , 23.74 ^° , 24.42 ^° , and 25.22 ^° . The non-solubilized crystals, hydrate crystals, solvated crystals, co-crystal crystals, and salt-type crystals as described in claim 1, wherein: the apple acid co-crystal crystal Type A of the compound of formula (I) has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 7.14 ^° , 8.77 ^° , 8.99 ^° , 9.90 ^° , 11.59 ^° , 11.84 ^° , 13.90 ^° , 14.72 ^° , 15.83 ^° , 17.27 ^° , 18.02 ^° , 19.21 ^° , 19.91 ^° , 20.22 ^° , 21.09 ^° , 22.98 ^° , 23.74 ^° , 24.42 ^° , and 25.22 ^° . The non-solubilized crystals, hydrated crystals, solvated crystals, co-crystals, and salt-type crystals as described in claim 1, wherein: the apple acid co-crystals Type A of the compound of formula (I) has a X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 7.14 ^° , 8.77 ^° , 8.99 ^° , 9.90 ^° , 11.59 ^° , 11.84 ^° , 13.90 ^° , 14.72 ^° , 15.83 ^° , 17.27 ^° , 18.02 ^{°, 18.49°} , 19.21 ^° , 19.91 ^° , 20.22 ^° , 20.49 ^° , 21.09 ^° , 22.32 ^° , 22.98 ^° , 23.74 ^° , 24.42 ^{° o} , 25.22 ^o , 25.58 ^o , 26.30 ^o , 27.04 ^o , 27.86 ^o , 28.46 ^o , 29.20 ^o , 29.84 ^o , 31.18 ^o , 31.42 ^o , 34.27 ^o , 34.82 ^o . The non-solubilized crystals, hydrated crystals, solvated crystals, eutectic crystals, and salt-type crystals as described in claim 1, wherein: the apple acid eutectic crystal Type A of the compound of formula (I) has an X-ray powder diffraction pattern as shown in Figure 60. The non-solubilized crystals, hydrate crystals, solubilized crystals, co-crystal crystals, and salt-type crystals as described in claim 1, wherein: the glycolic acid co-crystal crystal Type A of the compound of formula (I) has an X-ray powder diffraction pattern as shown in Figure 66. The non-solubilized crystals, hydrate crystals, solubilized crystals, co-crystal crystals, and salt-type crystals as described in claim 1, wherein: the glycolic acid co-crystal crystal Type B of the compound of formula (I) has an X-ray powder diffraction pattern as shown in Figure 68. The non-solubilized crystals, hydrate crystals, solubilized crystals, eutectic crystals, and salt-type crystals as described in claim 1, wherein: the p-toluenesulfonate crystals of the compound of formula (I) Type A have an X-ray powder diffraction pattern as shown in FIG34 . The non-solubilized crystals, hydrate crystals, solubilized crystals, eutectic crystals, and salt-type crystals as described in claim 1, wherein: the p-toluenesulfonate crystals of the compound of formula (I), Type B, have an X-ray powder diffraction pattern as shown in FIG36 . The non-solubilized crystals, hydrate crystals, solvated crystals, eutectic crystals, and salt-type crystals as described in claim 1, wherein: the p-toluenesulfonate crystals of the compound of formula (I) are of type C, whose X-ray powder diffraction pattern is shown in FIG38 . The non-solubilized crystals, hydrate crystals, solubilized crystals, eutectic crystals, and salt-type crystals as described in claim 1, wherein: the mesylate crystals of the compound of formula (I) Type A have an X-ray powder diffraction pattern as shown in Figure 44. The non-solubilized crystals, hydrate crystals, solubilized crystals, eutectic crystals, and salt-type crystals as described in claim 1, wherein: the mesylate crystals of the compound of formula (I), Type B, have an X-ray powder diffraction pattern as shown in FIG. 46 . The non-solubilized crystals, hydrate crystals, solubilized crystals, eutectic crystals, and salt-type crystals as described in claim 1, wherein: the mesylate crystals of the compound of formula (I) Type C have an X-ray powder diffraction pattern as shown in Figure 48. The non-solubilized crystals, hydrate crystals, solubilized crystals, eutectic crystals, and salt-type crystals as described in claim 1, wherein: the potassium salt crystals Type A of the compound of formula (I) have an X-ray powder diffraction pattern as shown in Figure 50. The non-solubilized crystals, hydrate crystals, solvated crystals, co-crystal crystals, and salt-type crystals as described in claim 1, wherein: the maleate crystals of the compound of formula (I) Type A have an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 4.26 ^° , 4.76 ^° , 7.08 ^° , 7.96 ^° , 8.54 ^° , 9.53 ^° , 10.18 ^° , 10.93 ^° , 13.89 ^° , 14.34 ^° , 15.03°, 15.99 ^° , 20.50 ^° , ^{21.49° ,} and 24.03 ^° . The non-solubilized crystals, hydrate crystals, solvated crystals, co-crystal crystals, and salt-type crystals as described in claim 1, wherein: the maleate crystals of the compound of formula (I) Type A have an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ): 4.26 ^° , 4.76 ^° , 7.08 ^° , 7.96 ^° , 8.54 ^° , 9.53 ^° , 10.18 ^° , 10.93 ^° , 12.41 ^° , 13.89 ^° , 14.34 ^° , 15.03°, 15.99 ^° , 17.93 ^° , 20.50 ^° , 21.49 ^° , 23.55 ^° , and ^{24.03° .} The non-solubilized crystals, hydrate crystals, solvated crystals, co-crystal crystals, and salt-type crystals as described in claim 1, wherein: the maleate crystals of the compound of formula (I) Type A have characteristic diffraction peaks at the following 2θ angles (±0.2 ^° ) in its X-ray powder diffraction pattern: 4.26 ^° , 4.76 ^° , 7.08 ^° , 7.96 ^° , 8.54 ^° , 9.53 ^° , 10.18 ^° , 10.93 ^° , 12.41 ^° , 13.89 ^° , 14.34 ^° , 15.03 ^° , 15.99 ^° , 17.93 ^° , 20.50 ^° , 21.49 ^° , 21.97 ^° , 23.55 ^° , 24.03 ^° , 25.19 ^° , 25.57 ^° , 26.00 ^o . The non-solubilized crystals, hydrate crystals, solvated crystals, eutectic crystals, and salt-type crystals as described in claim 1, wherein: the maleate crystals of the compound of formula (I) Type A have an X-ray powder diffraction pattern as shown in Figure 52. The non-solubilized crystals, hydrate crystals, solubilized crystals, eutectic crystals, and salt-type crystals as described in claim 1, wherein: the maleate crystals of the compound of formula (I) Type B have an X-ray powder diffraction pattern as shown in Figure 54. The non-solubilized crystals, hydrated crystals, solvated crystals, eutectic crystals, and salt-type crystals as described in claim 1, wherein: the sodium salt crystals Type B of the compound of formula (I) have an X-ray powder diffraction pattern as shown in Figure 56. The non-solubilized crystals, hydrate crystals, solvated crystals, eutectic crystals, and salt-type crystals as described in claim 1, wherein: the hydrochloride crystals Type A of the compound of formula (I) have an X-ray powder diffraction pattern as shown in Figure 62. The non-solubilized crystals, hydrate crystals, solvated crystals, eutectic crystals, and salt-type crystals as described in claim 1, wherein: the hydrochloride crystals Type B of the compound of formula (I) have an X-ray powder diffraction pattern as shown in Figure 64. A non-solubilized crystal E of a compound represented by formula (I), having a triclinic crystal form, and unit cell parameter values are: a = 9.63590(19) Å; b = 10.6920(3) Å; c = 12.4689(2) Å; α = 76.404(2) ^o ; β = 86.6962(16) ^o ; γ = 70.126(2) ^o ; space group: P-1; molecules per unit cell (Z): 2; unit cell volume: 1173.91 Å ³ ; calculated density: 1.376 g/cm ³ ; (I). A non-solvated crystal E of the compound represented by formula (I), whose X-ray single crystal diffraction pattern is shown in FIG15 ; (I).